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GENERAL INTRODUCTION AND OUTLINE OF THE THESIS
Hip fracture incidence
Osteoporotic fractures in elderly patients have become a major burden on public 
health resources [1]. Recent epidemiological studies report lifetime risks of any 
fracture of the hip, spine, and forearm of around 40% for women and 13% for men 
[2]. In 2010, approximately 2.5 million new osteoporotic fractures occurred in Europe’s 
largest countries (France, Germany, Italy, Spain, UK) alone [2]. Of these fractures, the 
hip fracture and subsequent hip fracture surgery have the most devastating impact 
on a patients’ life, with repercussions that extend beyond the traumatic injury into the 
domains of medicine, rehabilitation, psychiatry, social work, and health care economics 
[3, 4]. 
In the Netherlands, between 2000 and 2004, an average of 17,000 patients with 
a hip fracture were admitted per year [5]. Between 2009 and 2011 this average number 
was 19,700 patients [6]. An increase of 16% in hip fracture incidence over a period of 
10 years. With demographic changes and increasing life expectancy in industrialized 
countries, a doubling of the incidence of hip fractures can be expected by the year 
2050. By that time the worldwide incidence is estimated to reach a staggering 6.3 
million hip fractures per year [7, 8].
Sequelae of hip fracture surgery
Hip fracture surgery is associated with high morbidity and mortality. In the first 3 months 
after surgery, the mortality risk is increased five- to eight-fold [9, 10] – an excess risk that 
might persist for several years thereafter [11, 12]. The one-year mortality rate after hip 
fracture surgery can be as high as 32% [10]. Many patients – particularly those with 
mental illness, coexisting medical conditions and those suffering from postoperative 
complications – have a permanent reduction in activities of daily living and require 
postoperative discharge to an institutional care facility [13-16]. Half of all hip fracture 
patients will never recover to their pre-fracture functional capacity and 25% of these 
patients reside in a long-term care institution, 1 year after sustaining a hip fracture [9–
11[16]].
The costs of hip fracture surgery have a considerable impact on healthcare 
resources. Elderly patients aged 65 years and over, especially women, consume a 
disproportionate share of the trauma care budged, mainly caused by hip fractures [17]. 
The total cost in the USA, including the operation, in the first year after hip fracture 
surgery is US $ 26,000 per patient, [18] and the lifetime attributable cost of a hip 
fracture is calculated at US $ 81,300, of which nearly half (44%) is related to nursing 
facility expenses [19]. In the Netherlands, the total amount spent on hospital costs of 
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1patients with hip fractures is approximately € 500 million per year. (RIVM Kosten van Ziekten database 2013, www.kostenvanziekten.nl).
Second, contralateral hip fractures
Of those patients who survive the first fracture, up to 16% subsequently sustain a 
fracture on the contralateral side [20-22]. Taking previous predictions on future hip 
fracture incidence in account, the worldwide number of second hip fractures by 2050 
could well exceed 1 million per year. In contrast to the extensive documentation on 
the impact of first hip fracture surgery, the consequences of second, contralateral hip 
fracture surgery on the disability of these frail patients remain largely unknown. Limited 
data suggest that patients with a second hip fracture might have worse mobility shortly 
after the surgery compared to patients with a first fracture [23-25]. In a recent study of 
patients with a sequential hip fracture, the second injury was associated with greater 
loss of independent mobility and changes in residential status compared with single 
fractures at one-year follow-up [26]. Furthermore, in a cohort of 5,341 patients, Sawalha 
et al reported a significantly higher mortality rate, one year after a second hip fracture 
(31.6% vs 27.3%, P= 0.024) [27]. 
Prevention of first and second hip fractures
Given the detrimental impact of hip fractures on elderly patients, first and secondary 
fracture prevention efforts are clinically justified. Preventive measures thus far have 
been aimed at (1) the prevention of falling and (2) the prevention of fracture after 
falling. 
Fall prevention programs show a significant reduction in fall incidence and 
could therefore be a valuable new tool to improve mobility and independence of 
individuals with osteoporosis [28]. Training fall arrest strategies, such as martial arts 
fall techniques, could be useful to prevent hip fractures in persons with osteoporosis 
[29]. Of the existing balance exercises, Tai Chi Chuan has proved to be the most 
successful in decreasing falls [30, 31]. However, all fall prevention strategies can only be 
implemented provided that the training itself is safe. Future randomized trials among 
the elderly, octo- and nonagenarians, should examine the efficacy and safety of these 
fall prevention programs. 
Fracture prevention by treating osteoporosis medically, has shown its positive 
effect in multiple randomized trials [32, 33]. However, a considerable number of 
patients who have sustained one hip fracture do not receive adequate pharmaceutical 
treatment for osteoporosis [34]. Poor compliance with oral bisphosphonate therapy 
and the short time between first and second fracture have been shown to diminish its 
efficacy [35]. Therefore, alternative approaches have been developed for frail patients 
at particular risk of acquiring a second, contralateral hip fracture (i.e. older age with 
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weakened motor skills, visual impairment, dementia, respiratory disease or solitary life 
after first hip fracture). One example is a hip protector. This device offers an external 
mechanical protection with either hard-shell or silicone pads in the region of the 
greater trochanter [36]. However, compliance with the device in non-institutionalized 
patients at risk of a second hip fracture, remains a concern. Shock absorbing floors to 
prevent fall related injuries in permanent care facilities or in hospital geriatric wards 
have the potential of being cost effective but further research is needed to establish 
their efficacy [37]. Airbags to wear around the belt are currently being developed 
and under investigation. Prevention of fracture by cement femoroplasty has been 
suggested [38, 39]. Although, biomechanical cadaver experiments showed promising 
results on increased load to fracture, cement femoroplasty has some major drawbacks. 
The high temperatures of curing bone cement could cause osteonecrosis. Moreover, 
fractures that occur after a failed preventive cement femoroplasty are potentially more 
difficult to treat, comparable to peri-prosthetic fractures [40-42].
However, despite all these efforts and the introduction of the above-mentioned 
preventive measures, the overall incidence of first and second hip fractures has not 
decreased in the last decades [43, 44].
Aim of the thesis
The aim of this thesis is twofold:
1. Explore the prevalence and sequelae of second hip fractures in two areas in the 
Netherlands, and
2. Make a biomechanical and biocompatibility evaluation of elastomer femoroplasty 
(EF), a minimal invasive technique to potentially prevent hip fracture surgery.
Outline of the thesis
Part 1: Sequelae of second hip fracture surgery
In part one, we aim to evaluate the prevalence of second proximal femur fractures 
and the sequelae of consequent hip fracture surgery. In Chapter 2 and 3 we elaborate 
on the incidence of second hip fractures, the variation in fracture types and fracture 
treatment, complication rate and postoperative institutionalization after hip fracture 
surgery. 
Part 2: Elastomer Femoroplasty
In part two, we propose a minimally invasive technique to prevent the potentially 
devastating sequelae of a second hip fracture. This new technique, elastomer 
femoroplasty (EF) is mechanically evaluated in an ex-vivo model. Chapter 4 introduces 
13General introduction and outline of the thesis
1the operative technique of EF as a preventive modality to prevent contralateral hip fractures after ipsilateral hip fracture surgery. In Chapters 5 – 8 the feasibility of EF in 
an in vivo cadaveric biomechanical experiment is evaluated. In Chapter 9 we discuss 
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PART I
Sequelae of second hip 
fracture surgery
CHAPTER 2
A retrospective analysis 
of bilateral fractures 
during a 16-year period: 
localization and variation 
in treatment of second hip 
fractures
L.M. Kok 
T.J. van der Steenhoven
R.G.H.H. Nelissen
International Orthopaedics October 2011
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ABSTRACT
Evaluation of subsequent contralateral hip fractures was the aim of this study. For 
this retrospective analysis patients were selected from the database of the LUMC, a 
teaching hospital in the southwest of the Netherlands. We analyzed all patients with 
subsequent hip fractures between 1992 and 2007. Exclusion criteria were high impact 
trauma and patients with diseases or medication known to have a negative effect on 
bone metabolism.
A total of 1,604 hip fractures were identified. Possible predictive factors for the 
second fracture and descriptive statistics related to surgery were recorded (Hb and 
HT before and after the operation, total amount of intra- and postoperative blood 
loss, type of surgical treatment (implant), complications, time of death after the last 
fracture, time between arrival in the hospital and operation and hospital stay for both 
fractures). A total of 32 second hip fractures were identified (2%) at a mean of 27.5 (SD 
28.9) months after the initial hip fracture. The mean age at the first fracture was 77.2 
years (SD 11.7), and 27 of 32 patients were female. Of these 32 patients (64 bilateral hip 
fractures), 32 fractures were intracapsular (1 femoral neck, 31 sub capital) and 32 were 
extracapsular fractures (6 subtrochanteric, 26 transtrochanteric). Although 24 of the 32 
patients had identical first and second hip fractures, only eight out of 24 patients were 
treated with the identical implants.
There was a significant difference in Singh index between both hips at the time 
of the first fracture. There was also a significant difference in Singh index between the 
hip that was not broken at the time of the first hip fracture compared to itself after 
the second fracture. All other studied patient and fracture characteristics were not 
significantly different.
In this population the percentage of second hip fractures was relatively low 
compared to other studies. The choice of implants in this study shows that implants 
were chosen randomly. Because there is a significant difference in Singh index during 
first and second hip fracture, osteoporosis medication might reduce the incidence of 
second hip fractures.
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INTRODUCTION
The lifetime risk of sustaining a hip fracture is 17.5% in women and 6.0% in men [1]. 
Complications of hip fracture and consequent hip fracture surgery include death, 
disability, long-term care needs and loss of social independency [2]. Following hip 
fracture surgery, there is a one-year mortality rate up to 36% over the subsequent year. 
Half of the patients will be unable to walk without assistance, and half of them will 
require long-term domiciliary care [2-4]. Among survivors of a first hip fracture, there 
is a high incidence (5–20%) of second hip fractures [5, 6]. Half of all the hip fracture 
patients will never recover to their pre-fracture functional capacity and 25% of these 
patients reside in a long-term care institution, one year after sustaining a hip fracture 
[7]. Taking these facts into consideration, it is obvious that all our efforts should go 
towards preventing first and second hip fractures.
Different strategies to prevent hip fractures and consequent hip fracture surgery 
have been introduced to achieve a reduction in second hip fracture incidence [8-10]. 
An alternative approach to prevention could be femoroplasty of the contralateral hip 
during the surgery of the first hip fracture. Recently the results of cement and elastomer 
femoroplasty were published [11, 12]. Since femoroplasty with flexible elastomer is 
more likely to prevent intracapsular hip fractures, prediction of fracture localization 
of the second hip fracture based on the first hip fracture is necessary. Observations 
in other studies already indicate symmetry in the two fracture localizations. Although 
there are a lot of data available on first hip fractures, less is known about patients 
with a second hip fracture. Especially little is known about symmetry in localization of 
fractures, symmetry in implants, and patient-specific factors that differ between the 
first and second hip fracture. The aim of this study was to determine the prevalence of 
second hip fractures and to establish both the localization of the fracture and the type 
of the implant. We hypothesized that second, contralateral hip fractures often occur in 
a similar localization as the first. Ultimately this could lead to establishing preventive 
measures.
PATIENTS AND METHODS
All patients with a proximal femur fracture, admitted to the Leiden University Medical 
Centre between 1992 and 2007, were included in this retrospective observational 
study. Patients were selected from two databases at the Leiden University Medical 
Centre: the financial administration database since January 1992 up to December 2007, 
and from 1999 to December 2007 the database of the surgical operative (OPERA) codes 
of proximal hip fractures from the departments of Orthopedics and Traumatology / 
General Surgery. The second database was included in the search strategy to double-
check the financial administrative database. Selection criteria for the search strategy 
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in both databases were patients with two or more surgical procedures of the proximal 
femur with either osteosynthesis or a (hemi) arthroplasty. Second, only patients older 
than 50 years of age were included as this is the cut-off age used by the WHO for an 
increased risk for low energy impact fractures. Patients who had a bilateral (both left 
and right) hip fracture during the 16-year follow-up period were identified. Exclusion 
criteria were high impact trauma and patients with diseases or medication known 
to have a negative effect on bone metabolism (i.e. corticosteroids). The study was 
considered a form of good clinical practice with no extra involvement of patients, thus 
medical ethics approval was waived. After inclusion the paper hospital charts as well as 
the hospitals electronic database (Mirador) were used to collect the study variables. All 
radiographs of the bilateral hip fractures were scored as well. The variables scored were: 
age, gender, preoperative body weight, trauma mechanism, localization of the fracture 
at the preoperative radiograph (intracapsular: sub capital, femur neck; extracapsular: 
trochanteric, subtrochanteric), time between both proximal femur fractures, time 
between arrival at the hospital and the surgical procedure, preoperative comorbidity 
classification (American Association of Anesthesiologists [ASA]), type of treatment (i.e. 
type of implant), blood loss, pre- and postoperative hemoglobin (Hb) and hematocrit 
(Ht), length of hospital stay for each of the fractures, postoperative complications, 
and time between death and last hip fracture. Furthermore, osteoporosis medication 
(vitamin D, calcium and bisphosphonates) was noted at three time periods: before 
and after the first fracture, and after the second fracture. Finally, the radiographs 
(AP and lateral hip and pelvis) at the first fracture occurrence were assessed for the 
degree of osteoporosis (the Singh-index) [13]. The inter-observer variability was tested 
within two weeks (L.K.). In case of disagreement on the Singh index class, a second 
observer (R.N.) was consulted. Surgery was performed by several surgeons, both staff 
surgeons and residents under supervision of the two earlier mentioned specialties. All 
data were entered in an access database, which was converted to an SPSS database 
for analysis. Statistical analysis was performed using SPSS version 16.0. Agreement 
for implant choice, if the localization was the same for both fractures, was calculated 
using Cohen’s kappa statistics. Differences in parametric variables were tested with the 
t-test. Differences between non-parametric variables like the Singh index and ASA-
classification were tested with the Wilcoxon signed rank test.
RESULTS
A total of 1,604 patients had hip surgery between January1992 and December 2007. 
In this period 150 patients (9.4%) had two or more surgeries of the proximal femur. Of 
these 150 patients, 118 patients were excluded because of either high impact trauma, 
failing implants or diseases or medication (i.e. corticosteroids) known to have a negative 
effect on bone metabolism. Patients who had an arthroplasty for indications other than 
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a fracture (i.e. osteoarthritis, metastasis) were also excluded. Thus, 64 bilateral fractures 
in 32 patients (2.0%) could be identified to have a proximal femoral fracture after a low 
impact trauma. The mean age at the first fracture was 77 years (SD 11.7) and for the 
second fracture 80 years (SD 11.3) (Table 1). 
Table 1. Patients characteristics
Characteristic Fracture 1 Fracture 2
Age (y) Mean: 77.2 Mean: 79.6
SD:11.7 SD: 11.4




Weight Mean: 66 Mean: 66
SD: 16 SD: 15
Missing: 3 Missing: 5
Men Men
- Mean: 67 - Mean: 77
- SD: 25 - SD: 21
- Missing: 0 - Missing: 1
Women Women
- Mean: 66 - Mean: 64
- SD: 14 - SD: 14
- Missing: 3 - Missing: 4
Time between fractures (months) Mean: 27.5
SD: 28.9
Missing: 0
Hospital stay (days) Mean: 20.5 Mean:16.3
SD: 17.8 SD: 17.0
Missing: 0 Missing: 0
Operation time (min)a Mean: 79 Mean: 93
SD: 44 SD: 42
Missing: 0 Missing: 0
Pre-operative ASA 1: 2 1: 1
2: 24 2: 20
3: 5 3: 6
4: 0 4: 1
Missing: 1 Missing: 4
Time between arrival in hospital and operation 
(h)
Mean: 17 Mean: 14
SD: 11 SD: 9
Missing: 2 Missing: 0
>24 h: 8 >24 h: 5
- ASA 1: 1 - ASA 1: 0
- ASA 2: 6 - ASA 2: 3
- ASA 3: 1 - ASA 3: 1
- ASA 4: 0 - ASA 4: 0
- ASA unknown: 0 ASA unknown: 1
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Characteristic Fracture 1 Fracture 2
Blood loss (ml) Mean: 342 Mean: 275
SD: 492 SD: 197
Missing: 18 Missing: 16
Osteoporosis (Singh index, range 1–6) Fractured hip 1 Non fractured hip Fractured hip 2
1: 6 1: 2 1: 9
2: 4 2: 3 2: 2
3: 5 3: 4 3: 7
4: 3 4: 5 4: 5
5: 2 5: 4 5: 0
6: 2 6: 4 6: 1
Missing: 10 Missing: 10 Missing:8
Osteoporosis medication Before fracture 
1
After fracture 
1 After fracture 2
Yes:2 Yes: 3 Yes: 7
No: 17 No: 17 No: 13
Missing: 13 Missing:12 Missing:12
Trauma mechanism Stumbling: 18 Stumbling: 17
Staircase:1 Staircase: 0
Missing:13 Missing: 15
Anaesthetics General: 10 General: 10
Spinal: 22 Spinal: 19
Missing: 0 Missing: 3
Hb pre-operative Mean: 8.2 Mean: 8.0
SD: 1.0 SD: 0.9
Missing: 3 Missing: 7
Hb 1 day post-operative Mean: 6.3 Mean: 6.4
SD: 1.1 SD: 1.2
Missing: 16 Missing: 11
Hb 2 days post-operative Mean: 6.4 Mean: 6.6
SD: 0.6 SD: 1.0
Missing: 15 Missing: 13
Ht pre-operative Mean: 0.40 Mean: 0.38
SD: 0.04 SD: 0.04
Missing: 4 Missing: 10
Ht 1 day post-operative Mean: 0.30 Mean: 0.32
SD: 0.05 SD: 0.05
Missing: 16 Missing: 13
Ht 2 days post-operative Mean: 0.31 Mean: 0.32
SD: 0.03 SD: 0.04
Missing: 16 Missing: 16
SD standard deviation 
Hb Hemoglobin Unit = mmol/L; Ht hematocrit Unit = L/L 
Weight = in kg Hb = hemoglobin concentration in mmol/l Ht = hematocrit in l/l. 
Differences were significant only for gender, time between fractures and osteoporosis.
 The mean time between the first and second fracture was 27.5 months (SD 
28.9). Of all patients 27 were women, and five were men. Of the 32 patients 13 patients 
died during the follow-up period, with an average survival of 32 months after the 
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last hip fracture. The Kaplan-Meier survival curve of the patients after the second hip 
fracture is shown in Fig. 1.
Of the 64 bilateral fractures 32 were intracapsular, and 32 were extracapsular. 
The second hip fracture had the same localization as the first at the proximal femur in 
24 of the 32 patients (75%) (intracapsular, extracapsular; Table 2). Thirty-one of the 32 
intracapsular fractures were femoral neck fractures and one was a sub capital fracture. 
Six of the extracapsular fractures were subtrochanteric and 26 were trochanteric. 
In the group of patients with two intracapsular fractures (Table 3), five out of 
12 patients were given the same implant for both fractures. Of all patients with two 
intracapsular fractures, the first fracture was treated in six of the patients with a DHS, 
two patients were treated with a cannulated screw, and four with (hemi)arthroplasty. 
For the second intracapsular fracture two patients were treated with a DHS, two with a 
cannulated screw and eight with (hemi) arthroplasty.
In the group with two extracapsular fractures at the successive time intervals, 
the first and second occurring fracture were treated in three (25%) of the 12 patients 
with the same implant (Table 4). The other differences in implant choice for the first and 
second intra- and extracapsular fractures are shown in Tables 4 and 5.
The kappa for agreement in implant choice and for localization of fractures 
was 0.12 for intracapsular fractures and −0.23 for extracapsular fractures. The average 
hospital stay was 20.5 days (SD 17.8) for the first fracture compared to 16.3 days (SD 
17.0) for the second fracture. The mean operation time for the first fracture was 79 min 
(SD 44), compared to 93 min (SD 42) for the second procedure. The mean weight for 
.
Fig 1. Kaplan-Meier survival curve after second fracture
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women declined from 66 kg (SD 14) to 64 (SD 14) (P=0.62) between fractures. In men 
the opposite was noticed, as men gained weight between the first (mean 68 kg, SD 
25) and second fracture (mean 77 kg, SD 21; P=0.30). For both the first and second 
fracture the preoperative comorbidity (ASA) classification was 2 (range 1–4). The 
trauma mechanisms involved falls while walking, except for one fall from the first 
step of a staircase (30 cm height) leading to a first hip fracture. For both the first and 
second surgeries 10 patients received general anesthesia and 22 had loco regional 
anesthesia. There was no significant difference in blood parameters between the first 
and second hip fracture. The mean time between arrival at the hospital and surgery 
was 17 hours (SD 11) for the first fracture and 14 hours (SD 9) for the second fracture. 
Eight patients with a first hip fracture had surgery 24 hours or more after arrival 
at the hospital, compared to 5 patients for the second hip fracture. Osteoporosis 
medication (Calcium, vitamin D, bisphosphonates) was given to 2 patients before the 
first fracture, to 3 patients after the first fracture, and to 7 patients after the second 
fracture. Information about medication was missing from 12 patients. There was a 
significant difference in Singh index when the first fracture (range 1–6) was compared 
to the non fractured contralateral hip (range 1–6; P= 0.007), and when the proximal 
femur at the time of the second hip fracture was compared to itself at the time of first 
fracture (range 1–6; P= 0.008, Wilcoxon test).
The mean number of complications after the first hip fracture was 1.0 
compared to 0.8 after the second fracture (Table 5). Six patients had complications 
in the operation area after a first and 4 patients after a second hip fracture. Nine 
patients had other, nonoperation wound- related complications after the first hip 
fracture and 8 after the second fracture.
Table 2. Distribution of fracture site per patient at the first and second occurring fracture
Fracture 1 Fracture 2
Intracapsular Extracapsular
Total
Subcapital Femur neck Trochanter Subtrochanter
Intracapsular
Subcapital 0 0 0 0 0
Femur neck 1 11 4 0 16
Extracapsular
Trochanter 0 3 8 0 11
subtrochanter 0 1 3 1 5
Total 1 15 15 1 32
Table 3. Choices of implant for intracapsular fractures at the first and second fracture
Fracture 1
Fracture 2
DHS Cannulated screw (Hemi)arthroplasty Total
DHS 1 1 4 6
Cannulated screw 0 1 1 2
(Hemi)arthroplasty 1 0 3 4
Total 2 2 8 12
DHS dynamic hipscrew (Synthes Inc)
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DISCUSSION
During a 16-year follow-up, the prevalence of bilateral proximal femoral fractures in the 
studied population was relatively low (2%) compared to other studies reporting a second 
hip fracture in 5–20% [5, 6, 14, 15]. One explanation could be that in our study patients 
with diseases or medication known to have a negative effect on bone metabolism 
were excluded. Another and more probable explanation is the variability in patient 
allocation. Since the Leiden region is a densely populated area with two hospitals with 
a trauma care unit, it is possible that a patient will be allocated to different hospitals 
for a first and second hip fracture. Furthermore, patients who were treated for a hip 
fracture in the LUMC after 2007 were not included in this study. Fractures occurring 
before 1992 were however noted from the hospital chart.
The survival of the patients in the present study is comparable to other studies 
[16]. The average time between arrival and operation in this study was short, which 
reduces mortality [17]. A possible explanation for the fact that patients often have 
Table 4. Choices of implant for extracapsular fractures at the first and second fracture
Fracture 1
Fracture 2
DHS Gamma-nail PFN Total
DHS 0 1 0 1
Gamma-nail 1 1 4 6
PFN 1 2 2 5
Total 2 4 6 12
DHS dynamic hipscrew (Synthes Inc); PFN proximal femoral nail (Synthes Inc); Gamma nail (Stryker Inc)
Table 5. Complications
Complications Fracture 1 Fracture 2
Number of complications Mean: 1.0 Mean: 0.8
0: 8 0: 10
1: 6 1: 7
2: 4 2: 0
3: 2 3: 3
Missing: 12 Missing: 12
Complications operation area
 Total 6 4
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the same type of fracture in both hips is that fractures have a multi-factorial cause, 
i.e., not only the bone mineral density and bone structure, but also geometry, play an 
important role [18].
An interesting finding in this study is the fact that both hips have a different 
Singh index at the time of the first fracture. The influence of immobilization on the 
occurrence of osteoporosis after the first hip fracture, as mentioned by some authors 
[19], will be little, since patients were ambulated the day after surgery. But since the 
degree of osteoporosis deteriorated further after the first fracture, it might have 
been prevented with adequate osteoporosis medication. In this study only seven 
patients of 32 received any form of osteoporosis medication (vitamin D, calcium and 
bisphosphonates). Also other studies show that osteoporosis is seldom treated after 
a hip fracture [15, 20]. Treating all patients with osteoporosis after a first hip fracture 
could prevent 43% of the second hip fractures [21]. In none of the patients a DEXA-
scan was made, but according to the Singh index at least half of the patients suffered 
from osteoporosis at the time of the first fracture, but they did not receive medication 
afterwards. When operating hip fractures diagnosing osteoporosis is very important. 
A Singh index on a regular X-ray can give important information about the degree of 
osteoporosis. Treating osteoporosis should always be considered, as it can prevent 
further hip fractures. Osteoporotic fractures are known to be preceded by a decline 
in weight, due to a decline in estrogens in postmenopausal women [22]. In this study 
the 3 kg difference was not a significant decline in weight for women, probably due to 
under power of the study. The hospital stay in this study is relatively long. The cause 
of this is unknown, but a hypothesis is that it is relatively difficult to find places for 
patients in nursing homes. Another explanation is that a few patients suffered from 
many complications and for that reason had prolonged hospital admissions, which 
contributes to a long average stay. An interesting but not significant (P= 0.34) finding 
in this study is the shorter hospital stay after a second hip fracture. Others suggest that 
the recovery of patients with a subsequent, contralateral hip fracture is not different 
from the first hip fracture [23].
Although 24 of 32 patients had a similar localization of the femoral fracture, only 
eight out of these 24 patients received the same implant in both hips. A factor that has 
to be mentioned is that Gamma-nails and PFN are implants of the same type, but used 
by different specialists. If the Gamma-nail and PFN are considered to be a comparable 
implant, 14 of these 24 patients received the same type of implant. The main reason 
to choose an implant is the type of fracture [24]. Undisplaced intracapsular fractures 
should be treated, according to the Dutch guidelines, with internal fixation using a 
method that is familiar to the surgeon [24].
According to the AO guideline there is no evidence of the superiority of one 
implant over the other for the fixation of intracapsular fractures. However, patients 
with a short life expectancy or low mobility demand are considered eligible for hemi-
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arthroplasty. The latter is known to have a lower risk of failure than a DHS or cannulated 
screws in these patients [24]. But also other characteristics of the fracture (bone 
quality, displacement and comminution) and patients characteristics (age, functional 
level before the fracture) are important [4]. Internal fixation with screws and nails is 
associated with less initial operating trauma, but has an increased risk of re-operation 
compared to hemi-arthroplasty [25]. Also co-morbidity is an important factor in 
choosing an implant. Parkinson’s disease, rheumatoid arthritis or osteoarthritis patients 
for example require total hip replacement as they have a high risk of postoperative 
prosthetic dislocation [4]. Probably one of the most important reasons to choose a 
specific implant is preference and experience of the surgeon. Research showed that 
treatment choice based on physiological status does not significantly improve clinical 
decision-making. This study showed clearly that implants were randomly chosen, 
instead of trying to give the patient symmetrical hips.
CONCLUSION
This small series shows a significant effect of the radiographic osteoporosis appearance 
as measured with the Singh index on second proximal femur fracture occurrence
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To determine patient and hip fracture characteristics, early postoperative complication 
rate and need for institutionalization at time of discharge from the hospital in patients 
treated for a second, contralateral hip fracture.
Methods
During a six-year period (2003-2009) seventy-one patients (60 women and 11 men; age 
range 54 – 94 years) underwent first hip fracture surgery and subsequent contralateral 
hip fracture surgery at our hospital. Variables including age, gender, American Society 
of Anesthesiologists Classification (ASA), AO fracture classification, time between both 
hip fractures, rate and severity of early postoperative complications and destination 
of discharge were obtained from the electronic medical records. Data from both 
hospitalization periods were compared.
Results
Forty-six percent of second hip fractures occurred within two years after the first hip 
fracture. Following first hip fracture surgery 13 patients had one or multiple complications 
compared to 23 patients after second hip fracture surgery (P= 0.02). The mean time 
(± SD) between first and second hip fracture in patients without complications after 
the second injury was 4.3 (± 4.2) years, compared to 2.6 (± 2.1) years in patients with 
complications after the second injury (P= 0.03). The mean ASA classification of patients 
without complications after second hip fracture surgery was 2.6 (± 0.6) versus 3.0 (± 
0.6) in patients with complications (P= 0.04). After first hip fracture surgery 27 patients 
(38%) were discharged to an institutional care facility, whereas 72% of patients resided 
at an institutional care facility after a second hip fracture.
Conclusions
Early complication rate in patients sustaining a second, contralateral hip fracture was 
almost twice that documented after the first hip fracture. Following second hip fracture 
surgery, most patients resided in an institutional care facility. 
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INTRODUCTION
Hip fracture is a public health burden in elderly patients with repercussions that extend 
beyond the orthopedic injury into the domain of medicine, rehabilitation, psychiatry, 
social work, and health care economics[1]. There are over 300,000 hip fracture patients 
in the United States each year. Patients with mental illness, coexisting medical 
conditions and postoperative complications have a permanent reduction in activities 
of daily living and require postoperative discharge to an institutional care facility [2, 3]. 
After hip fracture, mortality risk is increased during the first three months 5 to 8 fold [4]. 
This excess risk also persists for several years thereafter [5, 6]. Of those who survive the 
first fracture, up to 16 percent subsequently sustains a fracture on the contralateral side 
[7, 8]. Assumed risk factors for such second, contralateral fracture include older age [7, 
9, 10], weakened motor skills [11], weakened cognitive function [7, 12, 13], respiratory 
disease [12] and solitary life [14]. 
In contrast to the extensive documentation of the impact of a first hip fracture, 
the consequences of a second, contralateral hip fracture on the disability of these frail 
patients remain largely unknown. Limited data suggest that patients with a second hip 
fracture might have worse mobility shortly after the surgery compared with patients 
with a first fracture [15, 16]. In a recent study of 473 patients with a sequential hip 
fracture, the second injury was associated with greater loss of independent mobility 
and changes in residential status compared with single fractures at one-year follow-
up [17]. However, Sawalha and Parker in their study of 633 patients who sustained a 
second, contralateral hip fracture, could not corroborate the decreased level of mobility 
at one-year follow-up [18]. The mortality rate in their cohort, on the other hand, was 
significantly higher after a second hip fracture at one year than after a first fracture. No 
data are available on the immediate postoperative outcome of patients after second 
hip fracture. 
The specific aims of this study were to compare (1) patient and fracture 
characteristics of first and second, contralateral hip fractures, (2) the early postoperative 
complication rate in both groups, and (3) the need for institutionalization at time of 
discharge from the hospital of patients after surgery for a second, contralateral hip 
fracture with those of the same patients after their first hip surgery. 
METHODS
Patient selection
The electronic medical records and X-ray images of all patients with hip fractures (ICD-
10 code S72.0 or S72.1) operated between 2003 and 2009 in the St. Elisabeth Hospital 
(Tilburg, The Netherlands) were reviewed to identify patients who were treated for both 
36 Chapter 3
a first and second, contralateral hip fracture. Patients under the age of 50 years at the 
time of injury, second, ipsilateral fractures and fractures following high-energy trauma 
were excluded from the study. 920 eligible patients underwent hip fracture surgery in 
the study period. Of these, 71 patients (prevalence 8%), 60 women and 11 men; age 
range 54 – 94 years, were treated for a second, contralateral hip fracture at our institute 
and were included in this study.
Data collection
The characteristics and outcome after the first and second fractures in the included 
patients were obtained from (1) the electronic medical record system and (2) a 
prospective complication database. 
Data were collected prospectively in the electronic medical record system 
including patient age, gender, medical history, AO classification of the fracture and the 
appropriate ICD-10 and billing code recorded upon each admission to the emergency 
department, time of hospital admission, American Society of Anesthesiologists (ASA) 
classification [19] and time of surgery. Finally, the electronic medical record was 
reviewed for the complete postoperative course, including in-hospital complications 
and mortality, date of discharge and destination of discharge.
As for the prospective complication database, the standard definition of a 
complication as formulated by the Association of Surgeons of The Netherlands was 
used: ‘A complication is any condition or event, unfavorable to the patient’s health, 
causing irreversible damage or requiring a change in therapeutic policy’. Complications 
were coded prospectively according to the Trauma Registry of the American College of 
Surgeons Committee on Trauma (TRACS) [20]. In addition, a free-text description of the 
complication was also recorded. As prospective registration of complications is known 
to be often incomplete and inconsistent, in this study all patient records were fully 
reviewed for non-registered complications and all entries were checked. Early post-
operative complications were defined as those occurring within 30 days of surgery. 
Complications were ranked according to the Clavien-Dindo classification based on a 
therapy-oriented, four-level severity grading (ranging from Grade I – minor risk event 
not requiring therapy – to Grade IV – death due to a complication) [21]. In-hospital 
mortality and mortality within 30 days of surgery were scored separately. As this was 
a retrospective review, no actual patient follow-up visit for the specific purpose of this 
study took place.
Statistical analysis.
Statistical analysis was done using Statistical Package for the Social Sciences Statistics 
18 (SPSS Inc., Chicago, Illinois). To compare complications in the 71 patients after their 
first and second hip fracture surgery with continuous data and a normal distribution, 
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a paired Student’s t-test was used. For nominal data following hip fracture surgery we 
used McNemar’s test, a non-parametric test. ASA classification during first and second 
hip fracture surgery was compared using Wilcoxon’s test. P values less than 0.05 were 
considered significant.
RESULTS
Patient and fracture characteristics (Table 1 and 2)
The mean time between first and second hip fracture was 3.4 ± 2.9 years (range 0.25 
- 12.6 years). Forty-six percent of the second hip fractures occurred within 2 years 
after the first hip fracture. The percentage of intracapsular hip fractures was 63% for 
the first fracture and 59% for the second fracture (P=0.50). According to AO fracture 
classification no significant difference between the first and second hip fractures was 
found. The fracture-types were similar with respect to intra- or extra-capsular location 
in 52 patients (73%). The mean time from arrival at the hospital to surgery and the 
duration of hospital stay were similar after first and second hip fracture surgery.
Table 1. Patient and fracture characteristics (n = 71 patients).
First hip fracture Second hip fracture P value*
Gender (n (%))
 Female 60 (85%) Same patients -
 Male 11 (15%) Same patients -
Age (years)
 Mean ± S.D. 80.0 ± 8.1 83.4 ± 7.7 <0.0001
 Range 54 – 94 56 – 95
Mean time between hospital admission and 
surgery (days) 0.9 ± 1.5 0.8 ± 1.0 0.56
Mean duration of hospitalization (days) 15.7 ± 15.4 13.4 ± 12.0 0.35
Type of fracture (n (%)) 0.50§
 Intracapsular 45 (63%) 42 (59%)
 Extracapsular 26 (37%) 29 (41%)
 Plus-minus values are means ± SD. *Student’s t-test, §McNemar’s test
Table 2. American Society of Anesthesiologists (ASA) classification of physical health 
(n = 71 patients).
First hip fracture Second hip fracture P value*
ASA classification (n (%)) 0.001
 1 2 (3) 1 (1)
 2 42 (59) 24 (34)
 3 24 (34) 39 (55)
 4 3 (4) 7 (10)
 Total 71 (100%) 71 (100%)
* Wilcoxon’s test
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The ASA classification prior to first hip fracture surgery was 2.4 (± 0.6) versus 2.7 
(± 0.7) prior to second hip fracture surgery (P= 0.001). The mean ASA classification of 
patients without complications after second hip fracture surgery was 2.6 (± 0.6) versus 
3.0 (± 0.6) in patients with complications (P= 0.04).
Postoperative complication rate (Table 3)
Following first hip fracture surgery 13 patients had one or multiple complications 
compared to 23 patients after second hip fracture surgery (P= 0.02). There was one 
patient with two complications after first hip fracture surgery (a urinary tract infection 
and wound infection) compared to four patients with two complications after second 
hip fracture surgery (technical failure and urinary tract infection; cardiac and technical 
failure; cardiac and deep wound infection; pneumonia and urinary tract infection). 
Out of the 13 patients with complications after first hip fracture surgery, only 5 had 
complications after the second fracture. Four of these 5 patients had complications 
after the second hip fracture surgery that were similar to the complication after first 
fracture (pulmonary, cardiac and two wound infections). 
Six patients with second hip fracture died in the hospital, and one additional 
patient died within 30 days of the second fracture, thus the mortality within 30 
days of surgery of the second hip fracture was 10%. According to the Clavien-Dindo 
classification, 1 grade III complication occurred after first hip fracture, compared to 7 
severe complications, grade III and IV, after second hip fracture. The mean duration 
between first and second hip fracture in patients without complications after the 
second injury was 4.3 (± 4.2) years, and 2.6 (± 2.1) years in patients with complications 
after the second injury (P= 0.03).
Table 3. The 30-day postoperative complication rate comparing first hip fracture and second, 
contralateral hip fracture (n= 71 patients). 
First hip fracture  
(n=71) 
Second hip fracture 
(n=71) P value
§
Complications (n) 14 26 0.02
Patients with complications (n) 13 23 0.02
Type of complication (n)
 Cardiac 4 6
 Pneumonia 1 4
 Wound infection 4 5
 Urinary tract infection 4 2
 Dislocation – technical complication 1 2
 Severe complication leading to death  
 (Type IV) 7
§ McNemar’s test, * 6 patients died during hospitalization, one patient died after discharge within 30 
days.
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Discharge institutionalization (Figure 1)
After first hip fracture surgery 27 patients (38%) were discharged to an institutional 
care facility, 44 patients (62%) returned to their original residence. After second hip 
fracture 24 patients who originally resided home were discharged to an institutional 
care facility and 23 of the 27 patients who already resided at an institutional care facility 
returned to the same residence. Eventually, 47 patients (72%) resided at an institutional 
care facility after the second hip fracture. 
DISCUSSION
In the present study, we compared patient and fracture characteristics, early 
postoperative complication rate, and the need for institutionalization at the time of 
discharge from the hospital in seventy-one patients treated at our hospital from a 
consecutive series of 920 first hip fractures. It is well known that a major operation 
in elderly individuals results in functional decline [22, 23]. It could be postulated that 
























First Hip Fracture Second Hip Fracture 
Figure 1. Destination outcome at discharge after first and second hip fracture
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in performance and physiological reserve as well. Such impairment of function in 
the older surgical patient is consistently identified as a predictor of subsequent poor 
postoperative outcome and the need for discharge to an institutional care facility [23-
25]. Thus an optimal treatment to insure a mobile independent patient is of importance. 
Other factors for higher complication and mortality risks are advanced age, absence 
of a partner, dementia, a lower pre-fracture level of ADL independency or mobility 
problems [25-27]. Also ASA-classification due to diseases affecting generic health might 
be increased. It is unknown whether a second, contralateral hip fracture is associated 
with an additional risk of postoperative complications and institutionalization after 
discharge from hospital. Some use a discharge score at admission in these, often frail, 
fracture patients, to facilitate an optimal postoperative rehabilitation and expectation 
course for both patients and their family as well for the treating physicians [28]. 
We found that the characteristics of our cohort were similar to those reported in 
the literature so far: the majority of patients with hip fracture were female (85%); almost 
half of the second, contralateral hip fractures occurred within two years of the first 
hip fracture; and the anatomical classification of contralateral fractures was identical 
to the primary fracture in more than two thirds of patients [10, 29, 30] [12, 18] [18, 
30, 31]. Approximately 8% of all hip fracture patients in our study sustained a second 
hip fracture, this is comparable to incidence rates found in the literature [7, 8, 10]. It 
could be possible that patients were brought to another institution for their second 
hip fracture. If so, the 8% could be an underestimate of the true incidence of second 
hip fractures. However, our hospital has a regional trauma function, therefore patients 
would have to relocate outside our region to be admitted to another hospital for their 
second fracture. 
The 30-day mortality rate after second hip fracture in our study is comparable to 
previously determined mortality rate from a single hip fracture at our institute. In this 
previous study published in 2010 the hospital mortality of a similar cohort of patients 
operated for a single pertrochanteric femoral fracture in our hospital was 11% [32]. 
In our study, significantly more patients had postoperative complications after 
the second hip fracture than after the first hip fracture, with close to twice the number 
of complications per patient after second hip fracture surgery (table 3). In addition, 
complications were more severe, according to the Clavien-Dindo classification, after 
second hip fracture compared to those documented after first hip fracture. One 
explanation for this increased complication rate might be that patients were inevitably 
older at the time of the repeat injury and were hence more susceptible to medical 
complications. In our study, patients were on average 3.4 years older at the time of 
second hip fracture. Older age has been linked to increased mortality rate after second 
hip fractures [7, 10, 18, 25, 33]. The question raises whether age itself is an independent 
risk factor for postoperative complications, eventually resulting in death, or that more 
chronic comorbidity and reduced physiological reserves are the true independent risk 
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factors. This last argument is supported by a significantly higher ASA-classification in 
patients with complications after a second fracture. However, the question whether 
age or ASA-classification contribute to a worse outcome after a second fracture, 
cannot be answered from the current data. In addition, no rigid method such as the 
Charlson Comorbidity Index which classifies comorbid conditions that might alter 
the risk of mortality has been used in the present study [34]. A logistic regression that 
corrects for all potential independent risk factors and confounders would be required, 
but is unreliable using the current data set. Although this is a limitation of our study, 
the mean age of patients with postoperative complications after second hip injury 
did not differ significantly from those without postoperative complications (83.3 ± 
7.1 years versus 83.6 ± 8.1 years, respectively). More importantly, the time interval 
between both hip fractures was shorter in patients with postoperative complications 
after second hip fracture as compared to those without. It has been shown that fewer 
than half of ageing patients recover to their pre-illness levels of functioning one year 
following hospitalization for acute illness [35-37]. Therefore, the finding that those 
patients who required a second intervention sooner had more complications suggests 
that these patients were likely in a state of lingering reduced physiologic reserve 
after the first fracture, as suggested by the higher ASA classification in these patients. 
Such accumulated frailty in geriatric patients has been associated with increased 
susceptibility to postoperative complications and the need for institutionalization after 
discharge [24].
Another limitation of the present study is that reliable information on pharmacy 
usage was not available at the time of hospital admission. This is due to the retrospective 
nature of our study; therefore we performed no analysis of this presence of drugs-
at-admission effect on complications. Patients who are admitted with a second hip 
fracture often use five or more drugs daily [38]. Polypharmacy, combined with repeat 
immobility [39], indwelling devices such as urinary catheters [40] and a nutritional 
status that deteriorates during hospitalization [41] have been shown to put frail older 
patients at risk of hospitalization-associated disability with resultant loss of ability to 
live independently [37]. This phenomenon is supported by the observation in our 
study that only approximately one third of the patients was able to return to their own 
home after treatment for second hip fracture.
The finding that postoperative complications and institutionalization after 
discharge from the hospital are increased in patients sustaining a second, contralateral 
hip fracture has implications for clinical care. Patients that are admitted with a second 
hip fracture, especially those with a relatively short period between the two hip 
fractures, might be good candidates for targeted interventions such as acute care of 
elders units (ACE) or geriatric evaluation and management (GEM) units. In such units 
a multidisciplinary team takes primary role in patient care to reduce the incidence of 
complications. Such units have been shown to increase the likelihood of functional 
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improvement by the time of discharge and lower the need for nursing home care [42]. 
The integration of individual consulting services such as physical therapy, occupational 
therapy and geriatrics into a multidisciplinary team has been particularly promising 
following hip fracture [37].
Given the detrimental impact of second hip fracture on elderly patients, 
secondary fracture prevention efforts are clinically justified. Randomized trials have 
shown that available osteoporosis therapies are effective in preventing secondary 
fractures [43, 44]. However, a considerable amount of patients who have sustained one 
hip fracture do not receive adequate pharmaceutical treatment for osteoporosis [45]. 
Poor compliance with oral bisphosphonate therapy and the short time between first 
and second fracture have been shown to diminish the efficacy of this treatment for 
secondary fracture reduction [46]. Therefore, in frail patients at particular risk of second, 
contralateral hip fracture (i.e. older age with weakened motor skills, visual impairment, 
dementia, respiratory disease, or solitary life after first hip fracture) alternative medical 
approaches such as an external mechanical protection with hip protectors might be 
considered [47] as well as balance training for patients [48]. A surgical option, although 
still in the experimental phase, is internal stabilization with bone cement or elastomer 
through femoroplasty of the contralateral hip during surgery of the first hip fracture is 
promising because of its instant protection potential and inherent compliance [49, 50].
In conclusion, the need for discharge institutionalization was increased and 
the early postoperative complications were almost doubled in patients sustaining a 
second, contralateral hip fracture compared to the first hip fracture. Prevention of these 
second hip fractures is urgently needed. 
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The concept of preventive 
elastomer femoroplasty in 
individuals with high risk 
of hip fracture





The increasing number of osteoporotic hip fractures in the expanding elderly 
population and its burden on healthcare resources call for urgent preventive action. 
Among numerous preventive therapies only bisphosphonates have proven to be 
effective in preventing osteoporotic fractures in large randomized trails [1, 2]. However 
discussion remains on the optimal duration of therapy. Furthermore, up to three 
quarters of patients are not compliant in using their osteoporosis medication, possibly 
due to the side effects of the medication [3]. This might be an explanation for the high 
incidence of second, contralateral hip fractures. Also, the late start of bisphosphonate 
therapy after the initial fracture could be a contributing factor since a considerable 
number of second hip fractures occur in the first 2-3 years after the first hip fracture, 
when the effect of the bisphosphonate on bone strength has not yet set in [4]. 
A different, preventive measure is a wearable orthosis, the Hip-protector. This 
protective underwear is either of the “crash helmet type” with a Carbon-fiber or nylon 
shell, covering the greater trochanter of the hip, or of the “energy-absorbing type” with 
a soft cushion made of materials like silicone or D3O®. Both of these systems aim to 
reduce the focused force beneath an estimated fracture threshold. When wearing a 
hip-protector an immediate effect on the incidence of hip fractures has been shown [5]. 
However they require patient compliance and are therefore an ineffective intervention 
in those living at home [6, 7]. 
Contrary to these previously proposed preventive measures, elastomer 
femoroplasty (EF) does not require patient compliance and will have an immediate 
preventive effect. This new approach does not aim to prevent the hip fracture itself, 
but aims to prevent dislocation after the fracture, thus enabling bone healing with 
fracture consolidation conservatively, without surgery. This conservative treatment is 
comparable to that used for non-dislocated fractures [8, 9]. 
The efficacy of this preventive EF will be optimal in those patients with a high 
risk of femur fracture. After ipsilateral hip fracture surgery with either osteosynthesis or 
hemiarthroplasty patients have an increased risk of acquiring a contralateral hip fracture 
of up to 16 percent [10-12]. Other factors that increase the risk of hip fracture include: 
older age [10, 12, 13], weakened motor skills [14], dementia [10, 15, 16], respiratory 
disease [15], solitary life [17] and radiographic osteoporosis at the hip (the Singh Index) 
[18]. Treating the contralateral hip of high-risk patients during ipsilateral hip fracture 
surgery might optimize the efficacy of preventive EF. The technique of preventive EF 
and its potential use in these high-risk patients will be discussed.




A schematic overview of the preventive strategy of EF is displayed in Figure 1. After 
ipsilateral hip fracture surgery with either osteosynthesis or hemiarthroplasty the 
contralateral hip is preventively treated with EF during the same operative session.
The intervention starts with sterile draping of a small area below the greater 
trochanter of the contralateral hip. A stab incision is made in the skin and blunt 
dissection towards the lateral cortex of proximal femur is achieved. Using fluoroscopy, 
a Kirschner-wire is positioned through the center of femur neck and head, not through 
the femur head. Over the wire a 3.5 mm hole is drilled. Through this 3.5 mm hole in the 
lateral cortex an excentric drill is used to drill a 10mm channel in the femur neck and a 
15 mm anchor in the femur head (Fig. 2). Through a 7-gauge trocar the channel is filled 
with the elastomer, starting proximally and retracting while filling the cavity. The stab 
incision is closed using a steristrip.
The Elastomer
The elastomeric compound that was used in our experiments is a polydimethylsiloxane 
(PDMS). For femoroplasty the material needed specific chemical and mechanical 
Fig 1. Schematic overview of the principal of preventive elastomer femoroplasty (EF). 1) Intact 
proximal femur. 2) 3.5 cm hole is drilled in the lateral cortex. 3) Eccentric drill creates cavity in the 
proximal femur en femur head. 4) Cavity in the proximal femur. 5) Cavity filled with elastomer. 6) 
Forces on proximal femur during impact and fracture. 7) Situation after fracture, the elastomer 
prevents fracture dislocation.
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properties: the material had to be non-toxic and cross-link isothermally in the presence 
of blood, without the release of toxic by-products. It should be injectable through a 
large bore needle, therefore the viscosity in the non-cross-linked form had to be low. 
The curing-time should be sufficiently long (5–10 min) to be able to complete the 
injection-process before the material becomes too viscous. When cured, it should be 
non-thrombogenic and the strength and durability had to be sufficient to withstand 
stresses during cyclic loading and unloading. Silicone-based elastomers meet the 
above requirements of blood compatibility and mechanical properties, furthermore 
they have been successfully used in vivo [19, 20].
The Silicone-based elastomer was developed by the Technical University of 
Delft, the Netherlands (Prof. van Turnhout MSc PhD, van den Berg MSc PhD and Alili 
MSc) [21]. The formulation consists of a two-component room temperature addition-
cure liquid silicone formulation, obtained from Viazym BV [ViaZym BV; Delft, the 
Netherlands]. These two components are:
-	 A platinum containing Vinyl terminated polydimethylsiloxane (PDMS) with 
an optimized molecular weight with regard to viscosity versus mechanical 
properties of the cured end-product (elongation to break, modulus). This 
component further contains surface-treated amorphous silica and a sesqui-
siloxane-like material called Vinyl Q, which is known to increase shear-strength 
of the final cured elastomer without an evident increase in viscosity.
-	 A methylhydro-dimethyl-siloxane copolymer containing vinyl terminated 
poly- dimethylsiloxane (PDMS). This component further contains surface-
treated amorphous silica and Vinyl Q. The substance has an average 
polymerization time of approximately 5 minutes. 
Fig 2. The principle of using an eccentric drill used to create a cavity in the proximal femur of a 
Sawbone.
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DISCUSSION
We propose a new and experimental preventive percutaneous approach to reduce 
the incidence of second, contralateral hip fracture surgery in high-risk patients. Careful 
analysis of biocompatibility and a phased introduction, like proposed for all new 
implants should be performed to have an optimal patient safety [22]. After this a cost-
effectiveness analysis is mandatory before any preventive measure is installed. 
Applying EF in the contralateral proximal femur immediate after ipsilateral 
hip fracture surgery is likely to take some extra surgical time and although minimal 
invasive, will cause some extra surgical trauma to the patient. Furthermore filling the 
proximal femur could cause the release of fat emboli in vivo, comparable to those 
occurring during cementation of a hip stem (i.e. hip arthroplasty). Future studies will 
have to focus on the effect of these extra surgical risks on morbidity and mortality. 
These results will then have to be compared to the increased morbidity and mortality 
after surgery of second, contralateral hip fracture surgery.
Considering that the likelihood of acquiring a second, contralateral hip fracture 
is high and health care costs of treating a second hip fracture are at leased 20 times 
higher than the expected cost of EF, this preventive measure could well be cost-effective. 
Patient selection based on factors that increase the risk of a second, contralateral hip 
fracture, such as high age, high Singh index on radiographic image and dementia [10, 
12, 15, 16, 18] will improve both clinical outcome as well as cost effectiveness of EF.
In vitro experiments on fracture load after EF have been done and show 
promising results [23, 24]. Additionally we have tested the dislocation loads after 
a fracture was created in an EF treated femur during cyclic loading and unloading 
[25]. We found dislocation loads that were considerably higher than the loads on the 
proximal femur during normal gait, suggesting that the patient can walk unrestrained 
on a fractured EF treated hip. Future in vivo experiments, for instance using roentgen 
stereophotogrammetric analysis (RSA) [22, 26, 27], will have to confirm our in vitro 
observations. 
In conclusion, EF is a new and experimental approach, which might have an 
impact in reducing the burden of second hip fractures on patient quality of life and at 
the same time have a positive effect on the use of our health care recourses. EF could 
well be a cost effective preventive strategy since the incidence of second hip fractures 
is high and the additional costs of contralateral EF during ipsilateral hip fracture surgery 
is expected to be low. In vitro results of EF with respect to both biocompatibility as well 
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CHAPTER 5
Augmentation with 
silicone stabilizes proximal 
femur fractures: an in 
vitro biomechanical study









Prevention of hip fracture surgery in the elderly imposes great benefit for patient care as 
well as for society. The incidence of contralateral, second hip fractures after hip fracture 
surgery is as high as 20%. Augmentation of the contralateral proximal femur with 
silicone femoroplasty during hip fracture surgery of the ipsilateral hip could be a new 
preventive strategy. This study compared the degree of dislocation after a controlled 
induced fracture between treated and control cadaver femurs.
Methods
Ten paired cadaver femurs were randomly assigned for silicone femoroplasty 
and biomechanically tested for fracture load and dislocation against their native 
contralateral control. A load-testing machine was used for fracture induction. All 
femurs were first fractured in a simulated fall configuration followed by dislocation in a 
“single leg stance” configuration. Dislocation was accessed using the AO-classification 
and measuring the Caput-Collum-Diaphysis angle.
Findings
Fracture loads were approximately 10% lower in the treated group (P= 0.304). Forces 
needed to dislocate the proximal femur fractures did not significantly differ in both 
groups nor did the fracture type and AO-classification. All treated femurs showed 
complete reposition according to Caput-Collum-Diaphysis angle after dislocation 
versus only two of the controls (P< 0.001).
Interpretation
From the results of this study we conclude silicone femoroplasty stabilizes the proximal 
femur by restoring hip geometry according to the Caput-Collum-Diaphysis angle after 
fracture. Future improvements in minimal invasive excavation and injection could 
make silicone femoroplasty an attractive alternative strategy in the prevention of hip 
fracture surgery in the growing population of low-demand, elderly patients.
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INTRODUCTION
Different strategies to prevent hip fractures and consequent hip fracture surgery have 
been introduced in the past decades [1-6]. However, these preventive measures have 
not yet led to a reduction in sequential or second hip fracture incidence [7].People 
sustaining one hip fracture are 5-9 times more likely to fracture their contralateral hip 
compared to age matched controls [8]. The 1-year risk of a subsequent fracture can 
be as high as 10% [9]. The lifetime risk of a second hip fracture has been estimated at 
20% but may be as high as 55% [10]. Prevention of osteoporosis should ideally begin 
in childhood in order to minimize bone loss during life [11]. Treatment of osteoporosis 
after hip fracture is probably too late to prevent second hip fractures in the first 2 
years, whereas preventive augmentation of the contralateral hip during ipsilateral hip 
fracture surgery could be an instantly available modality to reduce the incidence of 
second hip fractures.
Recently the results of femoroplasty-cement augmentation of the proximal 
femur as a means of fracture prevention have been published [12, 13]. The authors 
showed that cement augmentation increased the strength of cadaver femurs, but it has 
had no clinical use so far since temperatures associated with curing of cement are high, 
possibly causing osteonecrosis. Acquiring femoral shaft fractures or even acetabular 
fractures due to the increased strength of the proximal femur might be another contra-
indication for using cement augmentation [12, 13]. To overcome these disadvantages 
of cement augmentation we devised a method of intra-medullar femoroplasty of the 
proximal femur with an injectable silicon rubber. Our hypothesis was that silicone 
femoroplasty restores the geometry of the proximal femur after fracture. The goals 
of the present study were to evaluate (i) the amount of dislocation according to the 
Caput-Collum-Diaphysis angle after fracture and after loading in a single leg stance 
configuration, (ii) the fracture load of augmented femurs compared to the controls and 
(iii) the load until dislocation after fracture of augmented and control femurs.
METHODS
Ten pairs of osteopenic (6) or osteoporotic (4) human cadaveric femurs from donors 
with a mean age of 81 years (SD of 7.6 years) were used. Five donors were male and 
five donors were female. All cadaver femurs were obtained from the Department of 
Anatomy, Leiden University Medical Centre. Fixation and preservation of all cadavers 
was performed by injection of embalming fluid into the femoral artery, consisting of 
36% formaldehyde with a mixture of ethanol, glycerine, phenol, K2S04, Na2S04, NaHC03, 
NaN03 and NaS03.
To exclude the presence of focal bone pathology, plain X-ray’s were made of all 
specimens. The femoral Caput-Collum-Diaphysis angle, the so-called CCD-angle, was 
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measured from the plain anterior-posterior radiograph of each femur using IQ-view® 
web-viewer (V2.1.0, Image Information Systems Ltd., London). We calculated the degree 
of osteoporosis of each proximal femur using dual-energy X-ray absorptiometry (DXA) 
with a Discovery A, QRD scanner (Hologic Inc., Bedford, USA). All femurs were scanned 
in air. Osteopenia and osteoporosis were defined according to the WHO, using I-scores 
of, respectively, <-1 standard deviation and <-2.5 standard deviation from the young 
adult mean value (Report WHO Study Group, 1994).
From each pair, one femur was randomly selected for femoroplasty; the 
contralateral femur of the same donor was used as a control. We used a regular electric 
drill to drill a 10 mm hole in the femur assigned for femoroplasty. This channel was 
located centrally in the femoral neck reaching into the femoral head approximately 4-5 
mm short of the medial femoral head cortex. To achieve a reproducible hole all femurs 
were drilled using fluoroscopy with a mobile X-ray machine (Pulsera® Mobile C-arms, 
Philips Heathcare, Eindhoven, The Netherlands). After drilling this 10 mm hole we used 
a specially constructed eccentric drill bit to excavate the femoral head to a diameter 
of 14 mm. The drilled cavity was cleaned by pulsed lavage system (Interpulse Stryker®, 
Kalamazoo, USA).
Plain anterior-posterior and lateral radiographs and DXA-scans were made after 
drilling. Polydimethylsiloxane (PDMS, Via-Zym BV, Delft, The Netherlands) was injected 
into the proximal femur using a 50 cc syringe. PDMS is a silicone rubber composed of 
two components. It is widely used in vivo because of its physiological inert properties 
[14]. PDMS initially has a low viscosity, it cures without exothermic heat, there is no 
release or formation of by-products as it hardens (polymerization and cross linking) in 
a watery environment at 37° C [15]. The injected volume needed to fill each femur was 
registered. All femurs were placed with the femoral head pointing down to prevent 
the silicon from running out while curing. Although the curing time of our silicone 
is approximately 15 min at room temperature all femurs were left to rest for 24 h. 
During curing and in between examinations and tests the femurs were kept moist with 
cloths drenched in formaldehyde mixture. Plain radiographs were made to record the 
distribution of silicone.
Augmented and control femurs were biomechanically tested using a LR5 KPlus 
5 kN load testing machine with a XLC-50 K-Al load cell and NEXYGENP/us material 
test and data analysis software (Lloyd Instruments, Fareham Hants, UK) with a data 
acquisition rate of 8 kHz. All femurs were fractured by simulating a fall on the greater 
trochanter in a modified Hayes-fall configuration [16]. The femoral shaft was firmly held 
by a steel arm in a 20° angle from the horizontal plane and with the femur head 15° 
internally rotated (Fig. 1a). The load was applied using a silicone-coated cup attached to 
the crosshead of the testing machine. The crosshead moved with 2 mm/s and stopped 
automatically when the load cell registered an abrupt reduction in load of 50%. The 
recorded load was defined as fracture load. After each specimen was fractured, plain 
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anterior-posterior and lateral radiographs were made to determine the fracture type, 
AO-classification and to calculate the CCD-angle.
After a femoral fracture had occurred, each specimen was placed in the testing 
machine in a vertical position using a “single leg stance” configuration [17]. This fixture 
holds the femur in an upright position 20° from the vertical in the coronal plane with 
15° endorotation (Fig. 1b). The actuator moved with a speed of 1 mm/s and stopped 
when an abrupt reduction in load of 50% was detected. The recorded load was defined 
as dislocation load. After the drop in force the crosshead returned to its original position 
allowing spontaneous or silicone-induced reposition. Again plain anterior-posterior and 
lateral radiographs were made to determine the fracture type (subcapital, transcervical 
and trochanteric), AO-classification and to calculate the CCD-angle. From these data 
we determined the amount of dislocation between the initial fracture and the increase 
of dislocation at the fracture site after loading in the single leg stance configuration, 
based on the increase in CCD-angle and fracture classification.
Statistical analysis of the data was done using SPSS. Student-1 tests were 
performed to determine significance in fracture load, load until dislocation and 
CCD-angles, calculating P-values and 95% confidence intervals. P-values of <0.05 
were accepted as significant. Correlation between fracture load and DXA results was 
determined by calculating the Pearsons (r) correlation.
Figure 1. A: Simulation of fall on greater trochanter, the femur is fixed with 15° endorotation and 
20° angle with the horizontal plane. B: Single leg stance configuration, the femur is fixed upright, 
with a 20° angle from the vertical plane and 15° endorotation.
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RESULTS
All femurs were paired and randomly assigned to either SF or control. Therefore both 
groups were similar with respect to age and bone mineral density (BMD). Characteristics 
of the cadaveric femurs are displayed in Table 1. We used osteoporotic or osteopenic 
specimens with an average I-score of -2.14 (range: -1.3 to -3.5) and BMD 0.702 g/cm2 
(range: 0.519-0.839). DXA-scans made after drilling the channel for femoroplasty 
showed no significant decrease in bone mineral density (BMD 0.695 g/cm2 (range: 
0.515-0.836), T-score -2.2 (range: -1.3 to -3.5)).
During silicone injection there was no leakage of silicone through vascular 
penetrations in the proximal femur. The mean volume of PDMS per femur was 35 cc 
(range: 28-42 cc). The X-rays after filling showed a regular and reproducible pattern of 
silicone distribution in the head, neck and trochanteric regions of the proximal femur 
(Fig. 2).
Fracture and dislocation loads for each femur in both control and SF group are 
displayed in Table 2. The mean fracture load in the simulated fall configuration was 
3097 N for the control group versus 2795 N for the SF group (P= 0.304, 95% CI of the 
difference: -929 to 325). There was a linear correlation between BMD and fracture load 
in both groups. The correlation coefficient for SF group r = 0.86 and for the controls 
r = 0.60. Forces needed to dislocate fractures (dislocation load) in a single leg stance 
configuration were 1436 N in the control group versus 1574 N in the SF group (P= 0.573, 
95% CI: -394 to 668). The stiffness during dislocation was 101 N/mm in the control 
group versus 119 N/mm in the SF group (P= 0.260, 95% CI: -16 to 53) with a maximum 
displacement of, respectively, 15 mm and 14 mm (P= 0.458, 95% CI: -2.8 to 1.4).
The CCD-angles measured before and after fracture and after dislocation are 
displayed in Fig. 3. Before fracture there were two outlying observations in CCD-angle in 
the control group, 123° and 125°, respectively. These outliers were approximately within 
2-3.5 interquartile ranges from the median of the observations and were accepted as 
normal variations in anatomy. In the control group the CCD-angels were 129° (range: 
124-133) after fracture and 113° (range: 93-140) after loading until dislocation. In 
the SF group the CCD-angles after fracture and after loading until dislocation were, 
respectively, 130° (range: 123-134) and 128° (range: 121-133). In the control group only 
Table 1. Baseline characteristics of cadaver femurs in both groups, BMD: Bone Mineral Density, 






BMD 0.703 g/cm² (±0.111) 0.702 g/cm² (±0.120)
T-score -2.14 SD (±0.74) -2.14 SD (±0.81)
CCD-angle 129° (±3) 128° (±4)
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two femurs had either spontaneous reposition of the fracture elements or a minor 
dislocation without alteration of the CCD-angle. Whereas all 10 SF augmented femurs 
maintained pre-fracture geometry according to CCD-angle. In the control group the 
absolute differences in CCD-angle (ACCD) were 2° (range: 0-7) after fracture and 20° 
(range: 3-39) after dislocation. In the SF group the ACCD after fracture was 2° (range: 
0-4) and 1° (range: 0-4) after dislocation (P= 0.001, 95% CI: -27 to -10). 
There was a large variability in the distribution of subcapital, transcervical and 
trochanteric frac tures in both groups. In the control group there was one subcapital 
fracture, seven transcervical fractures and two trochanteric frac tures. In the SF group 
there was one subcapital fracture, five transcervical fractures and four trochanteric 
fractures. In the SF group three trochanteric fractures ran through the drill hole in the 
lateral cortex. These three fractures were stable after load bearing and no significant 
dislocation occurred.
AO-classification of the fractures in the control group showed a predominance 
of B2 (7) fractures, one B3 fracture and two Al frac tures. In the SF group there were four 
B2 fractures, one Bl fracture, three Al fractures and two A3 fractures.
Figure 2. X-ray image of a Silicone augmented proximal femur. The line marks the deposition of 
the Silicone.
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Table 2: Forces needed to break and dislocate the Silicone augmented and control femurs
Load until break (N)
simulated fall configuration
Load until dislocation (N)
“single leg stance” configuration
Femur pair # Control SF Control SF
#1 1920 3696 861 967
#2 2904 2052 2326 912
#3 1407 1372 878 913
#4 2767 2410 600 665
#5 3210 3299 1067 2279
#6 3136 3340 2492 2875
#7 2872 2009 1299 1215
#8 4649 3484 1285 806
#9 4710 3910 1832 2807
#10 3398 2381 1723 2297
Mean (SD) 3097(1030) 2795(856) 1436(638) 1574(883)
Figure 3. The measured CCD-angle of the SF group compared to the control group before 
fracture, after fracture and after loading*
(* loading in a “single leg stance” configuration until dislocation)
the fracture elements or a minor dislocation without alteration of the CCD-angle. 
Whereas all 10 SF augmented femurs maintained pre-fracture geometry according to 
CCD-angle. In the control group the absolute differences in CCD-angle (ACCD) were 
2° (range: 0-7) after fracture and 20° (range: 3-39) after dislocation. In the SF group 
the ACCD after fracture was 2° (range: 0-4) and 1° (range: 0-4) after dislocation (P= 
0.001, 95% CI: -27 to -10).  
 
 
Figure 3. The measured CCD-angle of the SF group compared to the control group 
before fracture, after fracture and after loading*. 
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DISCUSSION
Augmentation of the proximal femur could be a new preventive strategy to the 
increasing demand on healthcare resources of hip fractures and consequent hip 
fracture surgery. We tested a method of internal augmentation that does not necessarily 
increase the proximal femur strength but restores the geometry of the proximal femur 
in case of a fracture. Increasing the strength of the proximal femur to prevent future 
fractures by augmentation or enhancement with injectable cement (Femoroplasty) has 
also been proposed [12, 13]. However in case of a fall the energy is passed on to parts of 
the hip without augmentation, like the femur shaft or acetabulum. A fracture in those 
regions often requires more extensive surgery with subsequent increased morbidity 
and mortality [18-20]. The aim of augmentation with silicone is not prevention of 
fracture but prevention of fracture dislocation. We showed that SF restores proximal 
femur geometry according to CCD-angle after fracture. In our study the fracture load 
is not increased compared to the controls and fractures in the SF augmented hip 
therefore showed a similar distribution of subcapital, transcervical and trochanteric 
fractures compared to the control group. We did not observe femoral shaft fractures in 
our experiments.
The results from the DXA-scans show that in our experiments the drilling of 
a hole and excavation of the proximal femur has no significant negative effect on 
measured BMD. However the average load needed to fracture the proximal femur in 
the SF group was approximately 10% lower than the fracture load in the control group. 
Although this difference was not statistically significant, the large standard deviation in 
fracture loads limits the statistical power of our study.
The clinical implications of a 10% difference in fracture load are not well 
established because the risk of fracture is not based on proximal femur strength alone. 
However these results should be interpreted very carefully. Geometrically restored 
proximal femurs after a fracture are worse than no fracture at all. Risk of fracture 
versus benefit of restored geometry should be tested in a cost-benefit or Markov 
analysis. Furthermore careful selection of patients with the highest risk of falling and 
consequent contralateral fracture should be made. Finally, refinement of the technique 
towards minimal invasive introduction of PDMS could possibly overcome the reduction 
in proximal femur strength. Since the difference in fracture load between augmented 
and control femurs could well be contributed to the size of the entrance hole in the 
lateral cortex. Previous studies have in fact shown that the risk of pathological fracture 
of a femoral metastasis is increased with a cortical bone lesion size of >25-30mm [21-
23]. Although the size of our entrance in the lateral cortex was only 10 mm, it is still a 
considerable gap especially in the smaller femurs. This is confirmed by Kukla et al. who 
showed a decrease in failure force by 21% after removal of dynamic hip screw and 41% 
after removal of standard gamma-nail implant in a biomechanical cadaveric study [24]. 
The entrance hole in the lateral cortex can also explain the increase in trochanteric 
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fractures in our treatment group. In three of the SF augmented femurs the fracture line 
passed the entrance hole in the lateral cortex.
We used fixed specimens in this experiment. We justified this second choice 
material because our primary outcome was reduction of dislocation after fracturing 
and loading the proximal femur and not load of force. Furthermore each femur was 
tested to its native, fixed control. However it is still a limitation of our study since most 
biomechanical experiments are done with fresh frozen cadaveric bones.
No residual dislocation of the hip fractures was observed in our SF augmented 
group after a mean load of approximately 1500 N was imposed on the fractured 
femurs. In the control group however, only two femurs showed no significant residual 
dislocation (i.e. unchanged CCD-angles). These two controls had impacted subcapital 
fractures and were therefore stable enough to bear this load. The remaining eight 
fractured hips in the control group dislocated considerably (i.e. change in CCD-angle 
>13°).
Induced fracture dislocation defined by a sudden drop in load of force was seen 
in both groups at an average of approximately 1500 N. Hip contact forces with walking 
in a normal gait pattern are 2-3 times the body weight, ranging from 1500 to 2250 N in 
an 75 kg individual [25, 26]. This may exceed our dislocation load of 1500 N. However 
there are arguments to suggest that this is not a major problem. First of all we tested 
these cadaveric femurs without the influence of the hip joint capsule or musculature. 
These soft-tissues will considerably contribute to the stability of the silicone augmented 
femur fracture, as has been shown for non-stabilized fractures [27, 28]. Therefore the 
force needed to dislocate these fractures could be higher were we to test it with soft 
tissue. Secondly, after hip fracture or hip fracture surgery patients start to mobilize 
using walking aids and thus only loading with a smaller portion of their body weight. 
Pain after a hip fracture of an augmented hip will probably also restrict the patient 
from full weight bearing. This would reduce the load of force and therefore reduce the 
dislocation of the fracture elements possibly allowing impaction and consolidation.
PDMS is not a particularly stiff material like steel or regular ce ment. In fact our 
load displacement results show an average of 119 N/mm in the SF group. Continuous 
loading and unloading could cause movement in the fracture leading to complications 
like delayed or malunion of the fracture due to continuous movement in the SF 
augmented hip. In such cases or in the case of secondary dislocation, osteosynthesis 
by for example implantation of a dynamic hip screw or gamma-nail should not be a 
problem. Normal drills and instruments can easily penetrate the silicone augmented 
hip which is a major advantage over cement.
In conclusion we showed that silicone femoroplasty stabilizes the proximal 
femur by restoring hip geometry according to the CCD-angle after fracture. We also 
found that silicone femoroplasty using a 10 mm hole in the lateral femur cortex is likely 
to reduce the strength of an otherwise intact bone by approximately 10% and therefore 
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could increase the risk of fracture in the treated population. Future experiments should 
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ABSTRACT 
The purpose of this study was to test femur strength and the ability to prevent fracture 
displacement of two minimal invasive elastomer femoroplasty techniques. 
Methods
A total of sixteen fixed human cadaveric femur pairs were used. From each pair one 
femur was randomly assigned for elastomer femoroplasty. In these femurs we drilled a 
3.5 mm entrance in the lateral cortex. Cavities for the elastomer were created by: group 
A, balloon and group B an excentric drill. All femurs were fractured by simulating a fall 
on the greater trochanter. Neck-Shaft-Angles on plain anterior posterior radiographs 
were measured to determine fracture displacement.
Findings
There was no significant difference in fracture load between controls and treated 
femurs for group A, 2904 N (SD 1091) versus 2803 N (SD 627) and group B, 2773 N (SD 
747) versus 2597 N (SD 834). In group A the mean displacement was 35° (SD 14) for the 
control femurs and 3° (SD 2) for the treated femurs (P < 0.001). In group B the mean 
displacement was 38° (SD 10) for the controls and 8° (SD 13) for the treated femurs (P 
< 0.001).
Interpretation
The results of this study show that minimal invasive elastomer femoroplasty prevents 
fracture displacement of the proximal femur. We found no significant compromise in 
load-to-fracture after minimal invasive balloon or excentric drill femoroplasty. 
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INTRODUCTION
Hip fracture and consequent hip fracture surgery is associated with increased 
morbidity, functional decline, and death, as well as increased use of health care services 
[1]. Different strategies to prevent hip fractures have been introduced in the last three 
decades. These preventive measures have however not yet led to a reduction in second 
hip fracture incidence [2-8]. The one-year risk of a second hip fracture is still as high as 
10% [9]. The lifetime risk of a second hip fracture has been estimated at 20% but may 
be as high as 55% and people sustaining one hip fracture are 5-9 times more likely to 
fracture their contralateral hip compared to age matched controls [10, 11]. Treatment 
of osteoporosis after hip fracture is probably too late to prevent second hip fractures in 
the first 2 years. Ideally people at risk of osteoporotic fractures should begin treatment 
of osteoporosis in childhood in order to minimize bone loss during life [12]. 
Preventive stabilization or augmentation of the contralateral hip during 
ipsilateral hip fracture surgery on the other hand could be an instantly available 
modality to reduce the incidence of second hip fracture surgery in the high-risk patient. 
In a recently published study, we showed that elastomer femoroplasty (EF) prevents 
fracture displacement, however, the load to fracture was 10% percent lower in the 
femurs treated with EF [13]. Similar to previous biomechanical cadaver studies on 
proximal femur strength after implant removal, the decrease in load to fracture was 
attributed to the 10 mm diameter entrance hole in the lateral cortex [14]. 
Minimizing the entrance hole in the lateral cortex for EF using small entrance 
techniques could therefore reduce this decrease in load to fracture of the proximal 
femur. 
Unpublished pilot studies pointed out that injection of elastomer into the 
proximal femur without drilling a hole in the cancellous bone does not result in a 
sufficient volume of elastomer to restore geometry after fracture. Therefore after 
drilling the entry hole in the lateral cortex, a channel has to be created in the proximal 
osteoporotic femur to suit the elastomer. Two techniques are possible:  drilling a hole 
using an excentric drill or cancellous bone compression similar to kyphoplasty. The aim 
of the current study is to evaluate the effect of a 3.5 mm hole in the lateral cortex of 
the proximal femur with respect to the load to fracture. Furthermore two different EF 
techniques are compared, an excentric drill excavating technique and cancellous bone 
compression technique.
MATERIALS AND METHOD
A total of 16 pairs of osteopenic or osteoporotic femurs from human cadaveric donors 
were used. Five donors were male and 11 donors were female. The mean age of the 
donors was 76.8 years (SD 11.4). All cadaver femurs were obtained from the Department 
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of Anatomy, Leiden University Medical Centre. Fixation and preservation of all cadavers 
was performed by injection of embalming fluid into the femoral artery, consisting of 
36% formaldehyde (CH2O) with a mixture of ethanol (C2H5OH), glycerin (C3H5(OH)3), 
phenol (C6H5OH), potassium sulfate (K2SO4), sodium sulfate (Na2SO4), sodium carbonate 
(NaHCO3), sodium nitrate (NaNO3), and sodium sulfite (NaSO3).
To exclude the presence of focal bone pathology, plain X-rays were made of all 
specimens. The femoral Neck-Shaft-Angle (NSA) was measured from the plain anterior-
posterior radiograph of each femur. We calculated the degree of osteoporosis of each 
proximal femur using Dual-energy X-ray Absorptiometry (DXA) with a Discovery A, 
QRD scanner (Hologic Inc., Bedford, USA). All femurs were scanned in air. Osteopenia 
and osteoporosis were defined according to the WHO using T-scores of respectively < 
-1 standard deviation and < -2.5 standard deviation from the young adult mean value 
[15].
From each femur pair, one femur was randomly selected for femoroplasty; the 
contralateral femur of the same donor was used as a control. In the femurs selected 
for femoroplasty we used a regular electric drill to drill a 3.5mm hole with a standard 
Ø 3.5mm, length 165mm, drill bit (Synthes inc, Solothurn, Switzerland) in the lateral 
cortex and channel in the femur neck.
The femurs were than randomly assigned to two groups, group A and group 
B. In group A the cavity for EF in the femoral neck was created by compressing the 
cancellous bone with an inflatable balloon, KyphX Xpander inflatable bone tamp 
(Kyphon inc., Sunnyvale, USA). To make a solid ‘anchor’ in the femoral head we used 
the 20 mm excentric drill (fig1a). In group B the cavity for EF was created using a 
specially designed excentric drill set (Department of Fine Mechanics, Leiden University 
Medical Center) (fig 1b). We used a 15 mm excentric drill for the femoral neck followed 
Fig 1: Example of the balloon compression technique, using a kyphoplasty balloon (a) and an 
example of the 20 mm excentric drill in the femur head (b)
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by a 20 mm excentric drill to create the ‘anchor’ for the elastomer femoroplasty in the 
femoral head. To achieve reproducible cavities all femurs were drilled using fluoroscopy 
with a mobile X-ray machine (Pulsera® Mobile C-arms, Philips Healthcare, Eindhoven, 
The Netherlands). The drilled cavity was cleaned before EF by pulsed lavage system 
(Interpulse Stryker®, Kalamazoo, USA). Plain anterior-posterior and lateral radiographs 
and DXA-scans were made after drilling. 
The elastomer used in the experiments is a two-component room-temperature 
addition-cure liquid silicone formulation, obtained from Viazym BV (ViaZym BV; Delft, 
the Netherlands). The two components consist off: A platinum containing vinyl-
terminated polydimethylsiloxane (PDMS) with an optimized molecular weight with 
regard to viscosity versus mechanical properties of the cured end-product (elongation 
to break, modulus). This component further contains surface-treated amorphous silica 
and a sesquisiloxane-like material known as Vinyl Q, which increases tear-strength of 
the final cured elastomer without much increase in viscosity. The second component 
is a methylhydrodimethylsiloxane co-polymer containing vinyl-terminated PDMS. This 
component further contains surface-treated amorphous silica and Vinyl Q.  PDMS is 
widely used in vivo because of its physiological inert properties [16, 17]. The elastomer 
we used was designed to have a low viscosity initially, to cure without exothermic heat, 
without the formation of by-products as it hardens (polymerization and cross linking) 
in a watery environment [18, 19]. The elastomer was injected into the proximal femur 
using a commercially available injector gun. The two components of the elastomer 
were mixed at room temperature using a static mixer attached to the nozzle of the 
injector gun.
Filling the proximal femur took place under fluoroscopy to evaluate the 
distribution of the elastomer in the proximal femur. We continued filling until either the 
elastomer overflowed from the lateral cortex hole or came out of vascular penetrations 
in the femur neck. All femurs were placed with the femoral head pointing down to 
prevent the silicon from running out while curing. Although the curing time of our 
silicone is approximately 10 minutes at room temperature all femurs were left to rest for 
24 hours. During curing and in between examinations and tests the femurs were kept 
moist with cloths drenched in formaldehyde mixture. Plain radiographs were made to 
record the distribution of Elastomer. 
Treated and control femurs were biomechanically tested using a material test 
machine (LR5KPlus 5 kN,Lloyd Instruments, Fareham Hants, UK) with a load-cell (XLC-
50K-A1 Lloyd Instruments, Fareham Hants, UK) and material test  and data analysis 
software (NEXYGENPlus, Lloyd Instruments, Fareham Hants, UK) with a data acquisition 
rate of 8kHz. All femurs were fractured by simulating a fall on the greater trochanter in a 
modified Hayes-fall configuration [20]. The femoral shaft was firmly held by a steel arm 
in a 20-degree angle from the horizontal plane and with the femur head 15 degrees 
internally rotated (Figure 2).
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The load was applied using a silicone-coated cup attached to the crosshead of 
the testing machine. The crosshead moved with a speed of 2mm/s and stopped when 
a 75% reduction in peak load was recorded by the load cell. The recorded load was 
defined as fracture load. After each specimen was fractured plain anterior-posterior 
radiographs were made to calculate the NSA. In case of complete displacement of the 
fracture we defined the NSA as 180 degrees. 
After biomechanical testing the proximal femurs were immersed in sulphuric 
acid (H2SO4) until all cadaveric tissue was dissolved, and elastomer casts were left. 
The Elastomeric casts were rinsed thoroughly and volumes were measured by water 
immersion.
Statistical analysis of the data was done using SPSS (SPSS 16.0, SPSS Inc., Chicago, 
IL, USA).  Paired student–T tests were performed to determine significance in fracture-
load, load until displacement and NSAs, calculating P-values and 95% confidence 
intervals. P-values of <0.05 were accepted as significant. Correlation between fracture 
load and DXA results, and the correlation between fracture load and elastomer volume 
was determined by calculating the Pearsons (r) correlation.
RESULTS
The results of all treated femurs were compared to paired controls. Therefore, the 
treated and control femurs were similar with respect to age, bone mineral density 
(BMD) and NSA (Table 1).
Out of the sixteen femur pairs 18 femurs were osteopenic with a T score < -1 and 
> -2.5 (5 pairs in group A and 4 pairs in group B) and 14 femurs were osteoporotic with 
a T score <  -2.5 (3 pairs in group A and 4 in group B). The average T-score was -2.4 (SD 
0.8) in group A and -2.6 (SD 0.7) in group B. DXA-scans made after excavation of the 
Fig 2. Modified Hayes-fall configuration. The femur is fixed at an angle of 20° with the horizontal 
plane simulating a fall on the greater trochanter.
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proximal femur for femoroplasty showed no significant decrease in T-score -2.0  (SD 0.9) 
in group A and -2.3 (SD 0.7) in group B. 
Fracture loads for each femur in both groups are displayed in Table 2. In group 
A, the mean fracture load in the simulated fall configuration was 2904 N (SD 1091) for 
the controls versus 2803 N (SD 627) for the EF treated femurs (P= 0.742, 95% CI of the 
difference: -799 N – 597 N). This is a 3.5% drop in fracture load after EF treatment. The 
correlation coefficient between BMD and fracture load for the controls was r = 0.81 and 
for EF femurs was r = 0.79. 
In group B the mean fracture load in the simulated fall configuration was 2773 N 
(SD 747) for the controls versus 2597 N (SD 834) for the EF treated femurs (P= 0.534, 95% 
CI of the difference: -809 N – 458 N). This is a 6.3% drop in fracture load after treatment. 
The correlation between BMD and fracture load for control femurs was r = 0.45 and for 
the EF treated femurs r = 0.95. 
The NSAs measured on plain anterior-posterior radiograph before and after 
fracture in both groups are displayed in figure 3 and 4. The controls of femur pair 6,7 
and 8 from group A and the controls of femur pair 3, 4, and 5 were completely displaced 
after fracture and were scored as 180° NSA. 



























NSA 130 ° (5) 128 ° (5) 129°(6) 130°(6)
Table 2. Fracture load in Newton for both control and EF treated femurs in Group A and B
Group A
Balloon technique 




Fracture Force (N) in simulated fall 
configuration
Femur pair Control EF Control EF
#1 1817 2314 1820 1217
#2 1846 1522 2643 1813
#3 2008 3146 3513 2300
#4 2794 2807 2462 2400
#5 2726 2943 3210 3151
#6 4963 3207 2043 3288
#7 3276 2942 2480 2839
#8 3804 3546 4010 3770
Mean (SD) 2904 (1091) 2803 (627) 2773 (747) 2597 (834)
78 Chapter 6
In group A the mean NSA of the control femurs before fracture was 130° (SD 
5) and after fracture 165° (SD 14). This is a mean displacement (DNSA) of 35°. In the 
EF treated femurs the mean NSA before fracture was 128° (SD 5) and 132° (SD 4) after 
fracture. This is a DNSA of 4° (p < 0.001, 95% CI of the difference 21°- 43°). In group B 
the mean NSA of the controls before fracture was 129° (SD 6) and after fracture 167° 
(SD 13). This is a DNSA of 38°. In the EF treated femurs the average NSA before fracture 
was 130° (SD 6) and 138° (SD 17) after fracture. This is a DNSA of 8° (p < 0.001, 95% 
CI of the difference 16° - 43°). There were 2 outliers one in each group. In group A, EF 
treated femur number 2 after fracture had an outlying NSA of 123° but did not differ 
significantly from its pre-fracture NSA of 122°. In group B, EF treated femur number 3 
failed after fracture and was scored at 180° and therefore had an outlying observation. 
The mean volume of elastomer in group A, 18.5 ml (SD 2.4) was significantly 
higher than in group B 14.5 ml (SD 2.7), P=0.05 (95% CI -0.02 – 7.97 ml). The correlation 
between fracture load and volume in group A was r = 0.60, and group B, r = -0.47 both 
correlations were statistically non-significant. 
Fig 3. Boxplots of Neck Shaft Angle’s (NSA) in control femurs and elastomer femoroplasty treated 
femurs, before and after fracture in group A (balloon femoroplasty).
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DISCUSSION
Elastomer femoroplasty of the proximal femur is a new and promising preventive 
strategy to reduce the increasing demand on healthcare resources of hip fractures and 
their sequelae. We showed that EF prevents displacement of the fracture according 
to NSA. Out of the 16 femurs treated with EF only one femur failed and had complete 
displacement. The fracture in this femur ran through the femur head of both the treated 
and paired control femur. The elastomer had insufficient grip to prevent displacement 
in this case.
In addition to the prevention of displacement the results of this study show 
a positive effect of minimal invasive elastomer femoroplasty on the fracture load, 
diminishing the possible EF induced fracture risk that we saw in our previous study. 
In this previous study we drilled a 10 mm diameter entrance in the lateral cortex and 
found a 10% decrease in fracture load. The major difference with our present study 
is that we drilled a smaller, 3.5 mm diameter, entrance hole. It is likely that the non-
significant reduction in fracture load decrease after EF in our current experiment (3.5% 
Fig 4. Boxplots of Neck Shaft Angle’s (NSA) in control femurs and elastomer femoroplasty treated 
femurs, before and after fracture in group B (drill femoroplasty).
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for the balloon and 6.3% for the drill technique) can be contributed to the smaller 
diameter of the entrance hole. In vivo this 3.5 mm defect in the lateral cortex would 
close due to bone formation within a short period of time.
However the results of the fracture loads have to be interpreted cautiously. 
Since there was a large spread in fracture loads between femur pairs and between 
treated and control femurs from the same pair a statistical type 2 or beta error could 
be possible. A possible explanation for this large spread in fracture loads could be the 
differences in hip geometry between pairs and individual proximal femurs. Previous 
studies using cadaveric materials also found large standard deviations in the load to 
fracture [13, 21]. In future experiments with EF this large spread in fracture loads could 
possibly be decreased by using standardized composite bones. 
We used fixed specimens for our experiments. This is a limitation of our study 
since most biomechanical experiments are done with fresh frozen cadaveric bones. 
We justified this second choice material because each femur was tested to its native, 
fixed control. The results from the DXA-scans show that in our experiments the drilling 
of a hole and excavation of the proximal femur has no significant negative effect on 
Fig 5. Plain anterior posterior radiographs after fracture. Some of the radiographs are mirrored 
so that the EF treated side is projected on the right hand side of the picture. The correct sides are 
displayed in the upper corners of each radiograph, and are marked by L and R. Femur pair B3 is 
the only pair with a complete failure of the EF treated femur. 
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measured BMD. This suggests that DXA does not accurately assess the cancellous bone 
mass. Since the femurs in both control and treated groups did not significantly differ 
in fracture load, the role of cancellous bone on proximal femur strength is uncertain in 
these fixed cadaver femurs.
Reduction of hip fracture incidence by preventive EF is unlikely since EF does 
not increase fracture loads. However hip fracture surgery could be reduced since 
EF prevents the displacement of fracture elements according to NSA. Conservative 
functional treatment of these undisplaced hip fractures, with early reactivation 
and mobilization, can than be administered. This will diminish hip surgery related 
complications. Furthermore the mortality rate after conservative functional treatment 
as has been described after Garden 1 hip fractures is significantly lower compared to 
surgery [22, 23].
The polydimethylsiloxane elastomer we used is not a particularly stiff material 
like steel or regular cement. Increasing the strength of the proximal femur to reduce 
hip fracture incidence by augmentation or enhancement with injectable cement 
(Femoroplasty) has been proposed [21]. However, in case of a fall the energy is passed 
on to parts of the hip with no augmentation like the femur shaft or acetabulum. A 
fracture in those regions often requires more extensive surgery with subsequent 
increased morbidity and mortality [24-26]. On the other hand continuous loading and 
unloading in a fractured femur after EF stabilization could cause movement in the 
fracture leading to complications like delayed or malunion. In such cases or in the case 
of secondary fracture dislocation, osteosynthesis by implantation of a Dynamic Hip 
Screw or gamma-nail should not be a problem. Normal drills and instruments can easily 
penetrate the EF-treated hip. This is a major advantage over cement.  
Although rare, avascular necrosis occurs in the conservatively treated un-
displaced hip fractures in 2-11% [22, 23]. This could be a possible drawback of preventive 
EF. We also know that cement augmentation in unstable pertrochanteric fracture does 
not cause an increase in avascular necrosis [27]. Future studies should clarify the effect 
of EF on the vasculature of the femur head and proximal femur.
The balloon technique created a significantly greater cavity for the elastomer, 
however this did not result in significant differences in fracture loads or NSA between 
both groups. The quantity of the elastomer in the proximal femur did not significantly 
correlate with fracture load in either group. Again future experiments with standardized 
composite bones could overcome the difficulty of the large spread in fracture loads. 
From our previous experiments we know that displacement forces after EF 
tested in a single leg stance configuration are approximately 1500N. Hip-contact 
forces with walking in a normal gait pattern are higher, ranging from 1500-2250N in a 
75 kg individual [28-30]. However after hip fracture surgery patients start to mobilize 
using walking aids and thus only loading with a smaller portion of their body weight. 
Moreover, pain after a hip fracture of an EF stabilized hip, will probably also restrict the 
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patient from full weight bearing. This would reduce the load of force and therefore 
reduce the risk of secondary displacement of the fracture elements, allowing impaction 
and consolidation. Future cyclic loading and unloading tests in fractured femurs treated 
with EF will have to clarify these displacement forces.
We found that EF reduced even complex trochanteric fractures to normal 
geometry. However in vivo these instable, extra-capsular fractures are more likely 
to have secondary displacement after load bearing. Therefore, a careful selection of 
patients who are likely to acquire a transcervical fracture in the future should be made. 
Since the likelihood of identical fractures in both hips is as high as 75% [11, 31]. High-
risk patients with a transcervical hip fracture could be considered for preventive EF in 
their contralateral hip during primary hip fracture surgery. 
In conclusion this study shows that elastomer femoroplasty stabilizes the 
proximal femur by restoring hip geometry according to NSA after fracture. Furthermore 
minimal invasive balloon and excentric drill femoroplasty techniques did not reduce 
fracture force compared to paired control femurs. However these results have to be 
interpreted cautiously since sample size was small and standard deviations were high. 
Minimal invasive elastomer femoroplasty could be a promising new strategy to prevent 
hip fracture surgery. Future experiments should clarify its feasibility in-vivo.
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ABSTRACT
Elastomer femoroplasty is a novel and experimental approach in the prevention of hip 
fracture surgery. Previously, we published the results of an in vitro cadaveric experiment 
in which we showed a significant reduction of fracture displacement in treated femurs. 
The aim of the present study was to establish the failure loads and interfragmentary 
movement of fractured, elastomer femoroplasty treated, femurs during cyclic loading.
Methods 
16 cadaveric femurs were treated with elastomer femoroplasty and fractured in a 
simulated fall configuration. Each specimen underwent 10 cycles with a preload of 50 
N, starting with a peak load of 250 N followed by 10 cycles of 500N and continued with 
500N increments. The crosshead speed was 2 mm/s. The failure load, the number of 
completed cycles and crosshead extensions were recorded.
Findings 
The mean failure load was 2709 N (SD 1094). The number of completed cycles until 
failure was 60 (SD 22). The mean translation during maximum loading was 5.25 mm 
(SD 0.9). At 1500 N (two times the bodyweight of a 75 kg individual) the extension was 
3.16 mm. 
Interpretation 
Preventive elastomer femoroplasty leads to stabilization of the proximal femur after 
fracture. In a single leg stance configuration, cyclic loading with mean failure loads that 
well exceed the peak loads during normal gait is feasible. 
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INTRODUCTION
After an initial hip fracture patients have a 10% risk of acquiring a second, contralateral 
hip fracture in the first year and a lifetime risk that can be as high as 55% [1-3]. The 
introduction of countless preventive measures in the last three decades has not led to 
a decline in the incidence of second hip fractures [4, 5]. Furthermore the sequelae of a 
second hip fracture - i.e. higher morbidity and mortality compared to those related to 
a first hip fracture, a high complication rate and long-term disability requiring nursing 
home admissions - form a major burden on healthcare resources [6].
Recently we published the results of a biomechanical experiment on elastomer 
femoroplasty (EF): an entirely novel and experimental approach in the prevention of 
hip fracture surgery [7]. The main objective of EF is not to prevent hip fractures, but 
to prevent fracture displacement and therefore the need for hip fracture surgery. In a 
static in vitro study using cadaveric femurs, we demonstrated that EF reduces fracture 
displacement after monotonic loading. In these femurs, hip geometry according to the 
Neck-Shaft-Angle (NSA) was maintained after fracture. In theory, these undisplaced hip 
fractures in elderly, low-demand patients could be treated conservatively with early 
mobilization and without surgery.
The conservative treatment of undisplaced hip fractures, Garden type 1 and 2, 
with early mobilization and reactivation is well established and can lead to fracture 
impaction and consolidation [8-11]. However, high rates of secondary displacement 
have been reported. Secondary displacement is best treated surgically, be it with 
added morbidity and mortality [12]. The elastomeric stent that is formed in EF primarily 
prevents displacement of the fracture parts. Theoretically, the elastomeric stent would 
not only reduce displacement of hip fractures at the time of injury, but might also 
contribute to a reduction in the secondary displacement rates during conservative 
treatment of undisplaced hip fractures. To be successful though, the fractured EF 
treated femurs would have to withstand considerable forces that are comparable to 
those on the proximal femur during normal gait. These peak contact loads are well 
described in the literature and range between 2.0 – 2.7 times body weight [13, 14].
We hypothesized that the load to failure of fractured, EF treated femurs during 
cyclic loading exceeds the peak load during normal gait. Furthermore, we measured 
the displacement, and determined the correlation of load with elastomer volume. 
Finally, we compared the results of intra-capsular and extra-capsular fractured EF 




A total of 16 femurs (8 right, 8 left) were obtained from the Department of Anatomy, 
Leiden University Medical Centre. Eleven donors were female, 5 were male. The mean 
age was 76.8 (SD 11.4) years. Fixation and preservation of the cadavers was performed 
by injection of an embalming fluid into the femoral artery. The embalming fluid was 
produced by the Department of Anatomy, Leiden University Medical Centre, and 
consisted of 36% formaldehyde (CH2O) with a mixture of ethanol (C2H5OH), glycerin 
(C3H5(OH)3), phenol (C6H5OH), potassium sulfate (K2SO4), sodium sulfate (Na2SO4), 
sodium carbonate (NaHCO3), sodium nitrate (NaNO3), and sodium sulfite (NaSO3).
Plain X-ray’s were made of all specimens to exclude the presence of focal bone 
pathology. The femoral Neck-Shaft-Angle (NSA) was measured from the plain anterior-
posterior radiograph of each femur. We measured the degree of osteoporosis of each 
proximal femur using Dual-energy X-ray Absorptiometry (DEXA) with a Discovery A, 
QRD scanner (Hologic Inc., Bedford, USA). All femurs were scanned in air. Osteopenia 
and osteoporosis were defined according to the WHO using T-scores of respectively < 
-1 standard deviation and < -2.5 standard deviation from the young adult mean value 
(1994). 
After fracture, the proximal femurs were classified using the AO classification 
for proximal femur fractures. Sub trochanteric fractures and hip fractures that were 
completely displaced were excluded from cyclic testing.
Elastomer femoroplasty
The elastomeric compound, polydimethylsiloxane (PDMS, ViaZym BV, Delft, The 
Netherlands) was manually injected into the proximal femur using a commercially 
available, hand held injector gun (Mixpac, Sulzer, Haag, Switserland). PDMS is 
an elastomer composed of two components. It is widely used in vivo (e.g. for the 
augmentation of nasal and chin bones) because of its physiological inert properties 
[15, 16]. The elastomer we used was designed to have a low initial viscosity enabling 
injection through 8g needles. It cures without exothermic heat and without the 
formation of by-products as it hardens (polymerization and cross linking) in an aqueous 
environment [17-19]. 
Before filling, the femurs were prepared by drilling a 3.5 mm hole in the lateral 
cortex. A channel was made in the femur neck either with a 10 mm kyphoplasty balloon 
or a 10 mm excentric drill. Finally, a 15 mm excentric drill hole was made in the femur 
head to form an “anchor site” for the elastomer. After drilling, the hole was rinsed out 
using a pulsed lavage system (Stryker, Kalamazoo, Michigan, USA) and saline. 
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The two components of the elastomer were mixed at room temperature using 
a static mixer (Mixpac, Sulzer, Haag, Switserland) that is attached to the nozzle of an 
injector gun.
Filling the proximal femur continued until either the elastomer overflowed from 
the lateral cortex hole or exited vascular penetrations in the femur neck. All femurs 
were placed with the femoral head pointing down to prevent the silicon from running 
out while curing. Although the curing time of our silicone is approximately 10 minutes 
at room temperature all femurs were left to rest for 24 hours. During curing and in 
between examinations and tests the femurs were kept moist with cloths drenched in a 
formaldehyde mixture. Plain radiographs were made to record the distribution of the 
elastomer, which is a radiopaque material. 
Hip fracture generation
Biomechanical testing was done using an LR5KPlus 5 kN load testing machine with 
a XLC-50K-A1 Load-cell and NEXYGENPlus material test  and data analysis software 
(Lloyd Instruments, Fareham Hants, UK). Fractures were generated by simulating a fall 
on the greater trochanter in a modified Hayes-fall configuration [20]. The femoral shaft 
was held firmly by a steel arm at a 20-degree angle from the horizontal plane and with 
the femur head 15 degrees internally rotated (Figure 1). The load was applied using a 
silicone-coated cup attached to the crosshead of the testing machine. The crosshead 
moved with 2mm/s and stopped automatically when the load cell registered an abrupt 
reduction in load of 75%. The recorded load was defined as fracture load. After each 
specimen was fractured plain anterior-posterior radiographs were made to calculate 
Fig 1. Schematic display of simulated fall configuration used to generate hip fractures, after 
Courtney et al, 1995. The femur shaft is angled 20-degree from the horizontal plane, internally 
rotated 15 degrees. The load cell (LC) is attached to the crosshead of the tensile testing machine 
and travels with 2 mm/s.
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the NSA. In case of complete displacement of the fracture we defined the NSA as 180 
degrees. 
Construct stability
Cyclic axial loading to failure was then performed using the same tensile testing machine 
with stance-like load configuration (Frankel 1960) [21]. Each femur was cut 20 cm distal 
to the lesser tubercle and was cemented in a polyethylene cylinder using poly(methyl 
methacrylate) (PMMA) (Biomet Inc, Warsaw, IN). The femur with polyethylene cylinder 
was placed in a stainless steel holder and load was applied to the femoral head and 
directed within the coronal plane at 20° to the shaft axis (Figure 2). 
Starting with a 50 N preload, each specimen was subjected to 10 cycles of 
loading from 50 N (minimum) to 250 N (maximum), followed by 10 cycles of loading 
from 50 N to 500 N.  After successful completion of the 50-500 N series, the maximum 
Fig 2. Schematic display of stance-configuration used to evaluate mechanical behavior of EF-
augmented fractured femurs subjected to cyclic loading.  In this configuration the femoral shaft 
is oriented 20-degrees from the vertical in the axial plane. The load cell (LC) is attached to the 
crosshead of the tensile testing machine and travels with 2 mm/s. During testing, the maximum 
load was incremented onwards (by 250 or 500 N) after every tenth cycle.
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load was increased 500 N every ten cycles (i.e. to 50-1000 N, 50 - 1500 N, 50 - 2000 N, 
etc.) until failure. Failure was defined as either a decrease in the NSA of more than 5 
degrees as measured after every 10 cycles, or an abrupt reduction of 50% in the applied 
load as registered by the load cell during any given cycle. The maximum output load 
that resulted in the 5 degrees decrease in the NSA or the 50% reduction in applied 
load was defined as the failure load. The difference in the NSA before and after cyclic 
loading was visually measured with a transparent protractor at the end of the last cycle 
with the crosshead returned to its 50 N preload position. The lines through the center 
of the femur shaft and running through the center of the head and de femur neck were 
used as landmarks. All cyclic loading was performed using a triangular waveform, with 
crosshead speed of 2 mm/s.
Elastomer volume assessment
After cyclic testing the proximal femur was sawn off just below the lesser tubercle. The 
proximal femurs were submersed in sulphuric acid (H2SO4) until all cadaveric tissue 
was dissolved and only elastomer casts were left. The elastomeric casts were rinsed 
thoroughly and volumes were measured by water immersion. Correlation of the 
volume of elastomer to the fracture load, failure load, number of cycles and maximal 
extension was then calculated. 
Statistical analysis
Statistical analysis of the data was done using SPSS (SPSS 16.0, SPSS Inc., Chicago, IL, 
USA). Descriptive analyses were used to determine mean and standard deviations 
of fracture load, failure load and maximal extension at 1500 N in all femurs. Paired 
student–T tests were performed to determine significance in failure load and maximal 
extension between intra-capsular and extra-capsular fractures, calculating P-values and 
95% confidence intervals. P-values of <0.05 were accepted as significant. Correlation 
between fracture load and elastomer volume, between failure load and elastomer 
volume, between number of cycles and elastomer volume and between maximal 




A total of 16 cadaveric femurs treated with EF were fractured using the modified Hayes-
fall configuration. However, only 14 femurs were tested using the cyclic loading protocol 
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as 2 of the induced fractures were inherently unstable: one was subtrochanteric, and 
the second fracture included a fracture through the femoral head.
The mean BMD of the tested femurs (n = 14) was 0.67 g/cm2 (SD 0.09) and the 
mean T-score was -2.39 (SD 0.69). The mean fracture load was 2813 N (SD 683). Neck-
Shaft-Angle before fracture 129 degrees (SD 4.5) and after fracture 133 degrees (SD 
3.3). AO classification: 5 fractures were classified as intra-capsular, 31-B1 and 9 fractures 
were classified as extra-capsular, 31-A1 (n=5) A2 (n=1) and A3 (n=3). The baseline 
characteristics of the femurs divided by fracture location are displayed in Table 1. The 
NSA before fracture was significantly higher in the intra-capsular fractures 133 degrees 
(SD 2.3) versus 127 degrees (SD 4.4) in the extra-capsular fractures (P= 0.03, 95% CI 
0.6 – 9.9).
Fracture stabilization
The results of cyclic loading are displayed in Table 2. None of the femurs failed due to 
a decrease in NSA of more than 5° measured in-between cycles. For the intra capsular 
fractures (AO classification 31-B 1-3, n=5) the mean number of completed cycles was 53 
cycles (SD 24) and for the extra capsular fractures (AO class. 31-A 1-3, n=9) 64 cycles (SD 
21) (P= 0.40, 95% CI -37 – 16). The mean failure load for the intra capsular fractures was 
2399 N (SD 1339) and 2882 N (SD 978) for the extra capsular fractures (P= 0.45, 95% CI 
-2 – 867). The mean extension during maximal loading for the intra capsular fractures 
was 5.45 mm (SD 0.39) and 5.14 mm (SD 1.10) for the extra capsular fractures (P= 0.56, 
95% CI -0.81 – 1.43).
At 1500 N the mean extension of the crosshead was 3.16 mm (SD 0.82). For the 
intra capsular fractures the extension was 3.25 mm (SD 1.29) and for the extra capsular 
fractures 3.12 mm (SD 0.54), (P= 0.77, 95% CI -0.97 – 1.27).
Elastomer volume
The mean volume of injected elastomer was 16.8 cm3 (SD 3.3). The Pearson’s correlation 
(R) between injected volume and fracture load was r = - 0.05, between volume and 










P 95% CI of the difference
Age (years) 76 (9.9) 75 (9.4) 77 (13.6) 0.68 -15.0 – 10.0
Gender, m : f 5 : 9 1 : 4 4 : 5
BMD (g/cm2) 0.67 (0.09) 0.65 (0.10) 0.67 (0.10) 0.74 -0.13 – 0.10
NSA before fracture (o) 129 (4.5) 133 (2.3) 127 (4.4) 0.03 0.6 – 9.9
NSA after fracture (o) 133 (3.3) 135 (2.3) 131 (3.4) 0.78 -0.4 – 7.0
Fracture loads (N) 2813 (683) 2674 (955) 2890 (532) 0.59 -1 – 637
Elastomer volume (cm3) 16.8 (3.3) 15.2 (4.1) 17.7 (2.6) 0.19 -6.4 – 1.4
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failure load was r = 0.22, between volume and number of cycles was r = 0.32 and 
between volume and maximum extension was r = -0.30. 
DISCUSSION
This study was performed to establish the feasibility of elastomer femoroplasty (EF) 
in stabilizing the proximal femur after fracture. To do so, we cyclically tested fractured 
human cadaveric femurs that were prophylactically treated with EF before fracture. 
Our outcome variables were failure load and displacement during cyclic loading. In our 
previous experiments we demonstrated that EF prevents displacement of the proximal 
femur at the time of fracture [7, 22]. The present study shows that the failure load of 
fractured femurs during cyclic loading was 2709 N. This well exceeds the peak loads of 
approximately 1500 – 2025 N during normal gait in a 75 kg individual [13, 14].
The main objective of preventive EF is to reduce the degree of fracture 
dislocation, thereby reducing the number of displaced hip fractures. There are 
extensive data on the functional treatment of undisplaced hip fractures, with early 
mobilization and without surgery. Secondary displacement rates of undisplaced hip 
fractures published in the literature range from 14-46% [8, 10, 11]. Early resumption, 
i.e. within 48 hours after fracture presentation, of partial or full weight bearing leads 
to a higher secondary displacement rate but decreases the number of complications 
associated with prolonged bed rest [8]. In a prospective study of 247 patients, Cserhati 
et al discerned 16% of general complications with bed rest versus 3% for direct surgical 
stabilization [12]. In the present in vitro cadaveric femur experiment we found that 
secondary displacement of the undisplaced hip fractures occurred after cyclic loading 
with forces that well exceed the peak loads during normal gait. After regular hip 
fracture surgery or hemiartroplasty these peak loads could be considerably lower since 
post-operative pain constrains the patient from full weight bearing [23]. In fact Koval 
et al concluded that elderly patients who are allowed to bear weight as tolerated after 
operative treatment of a fracture of the femoral neck or an inter trochanteric fracture, 
appear to voluntarily limit loading of the injured limb to 51% during the first post-
operative week [24]. These patients have to be stimulated to walk and are prescribed 
pain relief medication to gradually reach 87% loading at 12 weeks. Comparable pain 
and consequent limited peak loads could theoretically be expected after hip fracture 
in an EF stabilized hip, diminishing the risk of secondary displacement. However, in 










P 95% CI of the 
difference
Failure loads (N) 2709 (1094) 2399 (1339) 2882 (978) 0.45 -2 – 867
Completed cycles until failure 60 (22) 53 (24) 64 (21) 0.40 -37 – 16
Extension at 1500 N (mm) 3.16 (0.82) 3.25 (1.29) 3.12 (0.54) 0.77 -0.97 – 1.27
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the event that EF fails to stabilize the fracture parts and secondary displacement does 
occur, or fracture healing is impaired in any other way, it would remain possible to 
stabilize the fracture with standard surgical osteosynthesis. We found that normal drills 
and prostheses can easily be used after EF. Further experiments will have to be done to 
evaluate the potential debris and its biological response after drilling in the elastomer 
filled proximal femur. 
We did not measure the exact inter-fragmentary movement. It is possible that 
the measured crosshead extension was an overestimate of the true inter-fragmentary 
movement due to flexibility in femur shaft and the stainless-steel stance-construct. 
Further in vitro experiments should be done to measure the exact movement in the 
fracture during loading. 
Inter-fragmentary movement during loading and unloading could lead to 
pseudarthrosis, pain and an increase in immobility. On the other hand inter-fragmentary 
movement also leads to increased callus fracture healing [25]. Therefore the dynamic 
fixation of fractures with minimally invasive surgical techniques, such as intra-medullary 
nailing, has become increasingly popular. These well-established techniques also lead 
to relatively large fracture gaps (larger than 5 mm) and considerable inter-fragmentary 
movements (0.2-5 mm) [26]. 
We did not find any statistically significant differences in the failure load 
or extension between intra capsular and extra capsular fractures. Beforehand we 
expected that latero-caudal fractures, i.e. extra capsular fractures, would benefit less 
from EF stabilization, considering the relatively medial position of the elastomer in the 
proximal femur. The absence of significant differences might either suggest that the 
elastomer inter-digitised in the trochanteric cancellous bone and thus created extra 
grip and stabilization, or that the design of the experiment was unable to show the 
difference between intra and extra capsular fractures. Further experiments are needed 
to determine whether EF treatment should be limited to those individuals that are 
expected to acquire an intra capsular second hip fracture. In that case, patient selection 
based on type and location of the primary fracture would be easy and reliable since 
second, contralateral hip fractures are identical to the first hip fracture in 75% of the 
cases [27].
There were certain additional limitations in our study design. First, there was no 
comparison of the performance of fractured EF treated femurs vs. controls. Fractured 
femurs that were not treated with EF were all completely dislocated and were therefore 
excluded from cyclic testing [7]. Future experiments should be performed to compare 
EF with other invasive preventive techniques. Another limitation is that we chose to 
perform our DEXA scanning in air rather than water. The main objective of the DEXA 
scans in the present study was to detect any outliers in the group rather than establish 
the exact t-score as a definition of osteoporosis. Furthermore, we used fixed specimens 
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instead of fresh frozen cadaveric bones. We justified this choice of material because 
each femur was tested to its native, fixed control in the simulated fall.
 In this in vitro cadaver study the femoral shafts and heads were constrained 
by our set-up. This is a simplification of the in vivo post fracture situation and could 
enhance progressive impaction of the fracture. The soft tissue and hip capsula that are 
present in vivo might add to the stability of the fracture. On the other hand, muscles 
and ligaments could cause rotational and distractive forces on the proximal hip. We 
did not test these forces in our in vitro experiment but they could lead to secondary 
displacement and therefore failure of the EF stabilization. 
When considering preventive EF in vivo the following issues should be 
discussed. Preventive EF in itself could increase the risk of second hip fracture. In our 
previous studies we found that EF resulted in a decrease of 5%-10% in load to fracture 
in a simulated fall configuration, though with the sample size we used, we failed to 
reach statistical significance. We attributed this possible decrease in fracture load to 
the 3,5 mm entrance in the lateral cortex. If this is the case in vivo the fracture risk 
after EF might diminish with the healing of the entrance hole over time. However, EF 
remains an invasive technique with possible complications including emboli, infection 
and hematoma. Furthermore, there is a risk that preventive EF does not result in second 
hip fracture healing. Therefore, only patients with a high risk of second fracture should 
be selected for preventive EF during first-hip-fracture surgery. Risk factors including 
female gender, older age, cognitive impairment and lower bone mass could be used in 
selecting these patients [1]. 
In conclusion, this in vitro cadaveric biomechanical study showed that EF 
prevents fracture displacement as assessed by the NSA, confirming our previous 
experiments. Cyclic loading of these undisplaced, geometrically unchanged hip 
fractures is feasible with failure loads that exceed the peak loads of normal gait. The 
limited inter-fragmentary movement and consequent risk of non-union will have to be 
quantified in future studies.
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In vitro cadaveric studies showed that elastomer femoroplasty (EF) prevents 
displacement of fracture parts after proximal hip fracture allowing for non-operative 
treatment. In the event that secondary displacement does occur, the purpose of the 
present study was to determine the feasibility of performing osteosynthesis of a 
fractured hip that has been treated with EF.
Methods
Ten pairs of human cadaveric femurs were fractured in a simulated fall configuration. 
From each pair, one femur was randomly selected for EF prior to fracture generation 
and the contralateral femur was used as control. Following hip fracture generation, 
osteosynthesis was performed in all femurs and the operative time, technical difficulties 
during the procedure, and postoperative failure-load were recorded. 
Results
The mean (SD) time to perform osteosynthesis was 20 (6) minutes in the control-group 
and 19 (5) minutes in the EF-group (P= 0.69). During osteosynthesis of the fractured 
hip in the EF-group, no difficulties (including the need for additional instruments to 
remove elastomer from the proximal femur) were recorded. Postoperative failure-load 
was similar in the control-group and the EF-group.
Conclusion
Fixation with routine osteosynthesis of displaced cadaveric hip fractures is not hindered 
by the presence of previously injected elastomer.
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INTRODUCTION
Among survivors of an initial hip fracture, up to 16% of elderly patients are at increased 
risk of sustaining a second, contralateral hip fracture [1, 2]. The risk of a second hip 
fracture increases with age [1, 2], weakened cognitive and motor function [3], respiratory 
disease [4] and solitary life [5]. Recent literature suggests that the outcome of surgery 
for a second, contralateral fracture may be worse than that of a first hip fracture [6-8] in 
terms of early postoperative complications, discharge institutionalization, independent 
mobility and survival [6]. 
Given the detrimental impact of a second hip fracture on elderly patients, 
different strategies have been proposed to prevent the sequential trauma, including 
pharmaceutical treatment for osteoporosis [9-11], external mechanical protection 
with hip protectors [12], and cement augmentation of osteoporotic bone [13, 14]. 
The injection of cement into osteoporotic cadaveric proximal femurs resulted in an 
82% increase in peak fracture loads for a simulated fall on the hip, compared to non-
injected femurs [15]. However, cement augmentation is associated with significant 
heat generation due to polymethyl-methacrylate polymerization. The exothermic 
reaction of cement could cause thermal necrosis of healthy bone and potentially 
lead to avascular necrosis of the femoral head [16, 17]. In addition, osteosynthesis of 
fractured femurs that were beforehand reinforced with cement may be challenging, 
with particular difficulty recorded in the removal of the composite [13].
We recently introduced the concept of elastomer femoroplasty (EF), i.e. preventive 
stabilization with elastomer, injected in the contralateral femur during ipsilateral hip 
fracture surgery [18-20]. Unlike cement augmentation, the intention of EF is not to 
prevent the occurrence of a second, contralateral fracture. In fact, fracture loads of EF-
treated cadaveric femurs were approximately 10% lower than those of non-augmented 
femurs [18]. Rather, EF has been shown to prevent displacement of the fracture as 
measured with the Neck Shaft Angle (NSA) directly after impact.  Similar to the well-
established conservative treatment of undisplaced hip fractures, Garden types 1 and 
2 [21], the prevention of fracture displacement by EF at the time of injury could result 
in primary fracture healing, thereby eliminating the need for a surgical intervention in 
these often, frail elderly patients. In addition, EF has been shown to prevent secondary 
displacement of the fracture during subsequent cyclic loading of cadaveric femurs [19, 
20]. In the event that EF fails to stabilize the fracture parts and secondary displacement 
does occur, fracture fixation with routine osteosynthesis should remain possible and 
equally stable compared to hip fractures without preventive EF. The objective of the 
present in-vitro biomechanical study was to determine the feasibility of performing 
osteosynthesis of a fractured proximal femur that has been treated with EF and its 
subsequent construct stability. We hypothesized that there is no difference in surgical 
time, difficulty in performing the osteosynthesis, or failure load after osteosynthesis of 
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fractured proximal femurs that were stabilized with elastomer femoroplasty (EF-group) 
and fractured proximal femurs without elastomer femoroplasty (control group).
METHODS
Cadaveric femurs
Ten pairs of human cadaveric femurs from donors with a mean age of 81 years (SD 
7.6 years) were obtained from the Department of Anatomy, Leiden University Medical 
Centre (LUMC). Five donors were male and five donors were female. Preservation of 
the cadavers was performed by injection an embalming fluid into the femoral artery. 
The embalming fluid consisted of 36% formaldehyde (CH2O) with a mixture of ethanol 
(C2H5OH), glycerin (C3H5(OH)3), phenol (C6H5OH), potassium sulfate (K2SO4), sodium 
sulfate (Na2SO4), sodium carbonate (NaHCO3), sodium nitrate (NaNO3), and sodium 
sulfite (NaSO3).
Plain radiographs were made of all specimens to exclude the presence of focal 
bone pathology. The femoral neck shaft angle (NSA) was measured from the plain 
anteroposterior radiograph of each femur using IQ-view web-viewer (V2.1.0, Image 
Information Systems Ltd., London). We calculated the degree of osteoporosis of each 
proximal femur using dual-energy X-ray absorptiometry (DXA) with a Discovery A, QRD 
scanner (Hologic Inc., Bedford, USA). All femurs were scanned in air. Osteopenia and 
osteoporosis were defined according to the WHO using T-scores of, respectively, < -1 
standard deviation and < -2.5 standard deviation from the young adult mean value 
(Report WHO Study Group, 1994).
Elastomer Femoroplasty
From each pair, one femur was randomly selected for elastomer femoroplasty (EF-
group, n=10). The contralateral femurs were used as control (control-group, n=10). 
Mean (± SD) bone mineral density (BMD) was 0.703 g/cm2  (0.111) in the control group 
and 0.702 g/cm2 (0.120) in the EF-group, respectively. Mean (± SD) T-score, a score used 
to express BMD in standard deviation from the mean BMD of a young adult, was -2.14 
(0.74) in the control group and -2.14 (0.81) in the EF-group, respectively. The mean (± 
SD) NSA in the control group was 129˚ (3) compared to 128˚ (4) in the EF –group.
Elastomer femoroplasty was performed as described in detail previously [18]. 
The femurs were prepared by drilling a 3 mm hole in the lateral cortex. A channel was 
made in the femur neck with a 10 mm excentric drill. Finally, a 15 mm excentric drill hole 
was made in the femur head to form an “anchor site” for the elastomer. After drilling, 
the hole was rinsed out using a pulsed lavage system (Stryker, Kalamazoo, Michigan, 
USA) using a saline solution. The elastomeric compound, polydimethylsiloxane (PDMS, 
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ViaZym BV, Delft, The Netherlands), was manually injected into the proximal femur using 
a commercially available, hand held injector gun (Mixpac, Sulzer, Haag, Switzerland). 
PDMS is an elastomer that has a low initial viscosity, cures without exothermic heat and 
without the formation of by-products as it hardens in an aqueous environment [22, 23]. 
Filling the proximal femur continued until either the elastomer overflowed from the 
lateral cortex hole or exited vascular penetrations in the femur neck. The mean volume 
of silicone per femur was 35 ml (range: 28–42 ml). The radiographs after elastomer 
filling showed a regular and reproducible pattern of silicone distribution in the head, 
neck and trochanteric regions of the proximal femur. 
Hip Fracture Generation
Biomechanical testing was done using an LR5KPlus 5 kN load testing machine with a 
XLC-50K-A1 Load-cell and NEXYGENPlus material test and data analysis software (Lloyd 
Instruments, Fareham Hants, UK). Fractures were generated by simulating a fall on the 
greater trochanter in a modified Hayes-fall configuration [24]. The femoral shaft was 
held firmly by a steel arm at a 20-degree angle from the horizontal plane and with 
the femur head 15 degrees internally rotated (Figure 1). The load was applied using a 
silicone-coated cup attached to the crosshead of the testing machine. The crosshead 
moved with 2mm/s and stopped automatically when the load cell registered an abrupt 
reduction in load of 75%. The recorded load was defined as fracture load (N). After each 
specimen was fractured plain anteroposterior radiographs were made to calculate 
the NSA. In case of complete displacement of the fracture the NSA was defined as 180 
degrees. The type of generated fracture was classified according to the AO-classification. 
Osteosynthesis
Simple and multifragmentary pertrochanteric (AO-A1 and AO-A2) fractures were 
treated with a dynamic hip screw (DHS) with a 4 hole plate and intertrochanteric 
(AO-A3) fractures were treated with a proximal femoral nail-antirotation (PFNA small, 
Synthes, Zuchwil Switzerland, length 200mm) following AO guidelines. The collum 
screws of both the DHS and the PFNA were placed with a maximum tip apex distance 
of 25mm, as noted in the study of Baumgaertner et al. [25]. During the osteosynthesis 
procedures, the operative time (min) and any technical difficulties during the procedure 
were recorded.
Failure Load Following Osteosynthesis
After osteosynthesis, each specimen was replaced in the load-testing machine in the 
same single leg stance configuration (Fig. 1). 
The actuator moved with a speed of 2 mm/s and stopped when an abrupt 
reduction in load of 75% was detected. The recorded load was defined as failure load 
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(N). X-rays of all three stages, fracture after EF- osteosynthesis after EF with fracture- 
after failure of osteosynthesis, are shown in figure 2.
Statistical Analysis
Statistical analysis was done using SPSS (SPSS 16.0, SPSS Inc., Chicago, IL, USA). Within 
the control and EF-group, proximal femurs were grouped according to implant used 
for osteosynthesis and descriptive statistics including mean and standard deviation 
were used. In addition, unpaired Student-T tests were performed to detect significant 
differences in operative time and failure load between the EF-group (n=10) and the 
control group (n=10). P-values were considered significant when <0.05. 
Figure 1. Graphic display of the single leg stance configuration, with the femur fixed upright at a 
20˚ angle from the vertical plane and 15˚ endorotation. The ‘L’ marks the load cell.
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RESULTS
After loading in both groups five fractures were pertrochanteric and five were 
intertrochanteric. In both the control-group and the EF-group, five out of ten 
osteosynthesis procedures were performed with a DHS and five out of ten procedures 
were performed with a PFNA (Table 1). 
The overall mean (± SD) time to perform osteosynthesis was 20 (± 6) min in the 
control-group and 19 (± 5) min in the EF-group. During osteosynthesis of the fractured 
hip in the EF-group, no difficulties including the need for additional instruments to 
remove elastomer from the proximal femur were recorded.
After osteosynthesis of the fractured hip no difference in overall mean failure 
load was recorded between the control-group and the EF-group (3783 ± 527 N and 
3472 ± 754 N, respectively) (Table 2).
DISCUSSION
The feasibility of performing standard osteosynthesis of a fractured proximal femur 
after preventive elastomer femoroplasty (EF) was evaluated in an in-vitro biomechanical 
study. We found no statistically significant differences in either operative time to perform 
osteosynthesis or postoperative energy-to-failure load between fractured human 
cadaveric femurs that were beforehand treated with EF and fractured proximal femurs 
without the elastomer stabilization. In addition, no technical difficulties or the need for 
Figure 2. X-rays of the cadaveric femurs with (from left to right) Fracture after EF; osteosynthesis 
after EF with fracture; after failure of osteosynthesis.
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specific instrumentation to remove the elastomer was necessary for osteosynthesis of 
the fracture in the EF group.
This feasibility study has certain limitations. We did not compare the performance 
of osteosynthesis in fractured hips augmented with elastomer with osteosynthesis 
in fractured hips reinforced with bone cement. The concept of femoroplasty with 
polymethyl-methacrylate (i.e. bone cement) as a prophylactic reinforcement of 
the femur has been introduced previously [14, 15]. Heini et al. injected cement into 
osteoporotic cadaveric proximal femurs [15]. By doing so, peak fracture load for a 
simulated fall on the hip was increased by 82%, with a corresponding increase in energy 
absorption of up to +188%, compared to noninjected femurs, indicating that cement 
Table 1. Time (minutes) required to perform osteosynthesis of the proximal femur in the control-
group and the elastomer femoroplasty (EF)-group, stratified by type of implant used. DHS, 
dynamic hip screw; PFNA, proximal femoral nail-antirotation.
Femur
Control-group EF-group Unpaired Student t-test
Implant Min Implant Min
#1 DHS 14 DHS 16  
P= 0.8852
#2 DHS 13 DHS 13
#3 DHS 18 DHS 17
#4 DHS 14 DHS 13
#5 DHS 13 DHS 12
Mean (SD) 14 (2) 14 (2)
#6 PFNA 28 PFNA 23
#7 PFNA 22 PFNA 24
#8 PFNA 28 PFNA 19
#9 PFNA 29 PFNA 22
#10 PFNA 20 PFNA 27
Mean (SD) 25 (4) 23 (3) P= 0.3171
Table 2. Failure load (N) after osteosynthesis of the proximal femurs in the control-group and 
the elastomer femoroplasty (EF)-group, with either proximal femoral nail-antirotation (PFNA) or 
dynamic hip screw (DHS).
Femur
Control-group EF-group Unpaired Student 
t-test
Implant Failure load (N) Implant Failure load (N)
#1 DHS 4510 DHS 3050
#2 DHS 3750 DHS 2450
#3 DHS 3200 DHS 5000 
#4 DHS 3930 DHS 2670
#5 DHS 3200 DHS 3560
Mean (SD) 3718 (550) 3346 (1016) P= 0.4920
#6 PFNA 3200 PFNA 4050
#7 PFNA 3680 PFNA 3940
#8 PFNA 4740 PFNA 2900
#9 PFNA 3820 PFNA 3640
#10 PFNA 3800 PFNA 3460
Mean (SD) 3848 (558) 3598 (455) P= 0.5717
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augmentation might prevent hip fractures in elderly patients. Unfortunately, cement 
augmentation was associated with significant heat generation due to polymethyl-
methacrylate polymerisation. In addition, osteosynthesis of fractured femurs that 
were beforehand reinforced with cement was a challenging procedure, with particular 
difficulty recorded in the removal of the composite [13].
As an alternative to bone cement to reinforce the proximal femur, we introduced 
femoroplasty using polydimethylsiloxane [18], an elastomer that cures without 
exothermic heat [22, 23]. The resultant construct stability of femoroplasty with 
elastomer is different from that with bone cement. Unlike cement augmented femurs, 
peak fracture load for a simulated fall on the hip in elastomer augmented femurs was 
not significantly different from untreated control femurs [18]. Dislocation according 
to Neck Shaft Angle was significantly reduced in the EF group [18, 19]. Furthermore, 
during subsequent cyclic loading, the failure load of fractured femurs stabilized by 
EF was 2709 N [20] - well exceeding the peak loads of approximately 1500 – 2025 N 
during normal gait in a 75 kg individual [26, 27]. These findings suggested that EF 
might both reduce initial displacement of hip fractures at the time of injury as well 
as reduce secondary displacement rates during subsequent conservative treatment of 
undisplaced hip fractures. In contrast to the data available on cement femoroplasty, 
we found in the present study that - if surgical stabilization was necessary after all, i.e. 
in the event of secondary dislocation - osteosynthesis of fractured femurs that were 
preventively treated with EF is not associated with any additional challenges. 
In this cadaveric study, we did not evaluate the presence of debris and its 
potential biological response elicited after osteosynthesis in EF treated hips. Elastomer 
is already widely used in-vivo, e.g. for the augmentation of nasal bones and in vascular 
grafts, because of its physiological inert properties [28-30]. These studies did not show 
any biological response. However, the biocompatibility of elastomer with the unique 
environment of cortical and cancellous bone and the marrow space is unknown. In 
addition, EF remains an invasive technique with possible complications including 
emboli, infection and hematoma. Future studies will have to investigate the in-vivo 
behavior of elastomer in fractured hips and subsequent osteosynthesis, and evaluate 
the cost-benefits of the intervention. An additional limitation of this study was that, 
similar to our previous experiments, we used fixed specimens instead of fresh frozen 
cadaveric bones. We justified this choice of material because contralateral side femurs 
were used for the control group.
There was a large variability in failure loads after osteosynthesis in the control-
group and the EF-group (Table 3). A possible explanation for this large spread in failure 
loads could be the differences in hip geometry between individual proximal femora. 
Previous studies using cadaveric materials also found large standard deviations in 
the load to fracture [15, 18]. Finally, the study sample was relatively small and more 
cadavers would be needed to reduce the chance of a possible type II error. However, 
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in the present feasibility study no clinically significant difficulties in performing 
osteosynthesis after stabilization with EF were encountered.
In conclusion, duration of surgery, difficulty in performing the osteosynthesis, 
and failure load after osteosynthesis of fractured proximal femurs that were stabilized 
with EF were comparable to the untreated contralateral femurs. This indicates that 
fixation with routine osteosynthesis of secondary displaced cadaveric hip fractures is 
not hindered by the presence of preventive EF.
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Customized Aortic Repair (CAR) is a new concept for endovascular aortic aneurysm 
repair in which a non-polymerised elastomer is injected to fill the aneurysm sac around 
a balloon catheter. Amongst other variables, the thrombogenicity of the elastomer 
should be tested, before further clinical experiments can take place. The aim of this 
human ex vivo study was to measure the thrombogenicity of the elastomer and to 
compare it to expanded polytetrafluoroethylene (ePTFE).
Design and materials
In a validated ex vivo model, non-anticoagulated blood was drawn from the antecubital 
veins of 10 healthy donors with a 19-gauge needle. It was drawn through elastomer 
tubes and through ePTFE Gore-Tex vascular grafts, both 60 cm long and with an inner 
diameter of 3 mm.
Methods
Fibrinopeptide A (FPA) and P-selectin expression was measured in blood samples, 
collected at the end of the grafts. After the experiments, the deposition of platelets and 
fibrin onto the grafts was visualized by scanning electron microscopy.
Results
For these graft types, a progressive increase in FPA production was observed in time. 
No significant difference was observed between the elastomer and ePTFE grafts (p 
> 0.05). No increase in P-selectin expression, and thereby no platelet activation, was 
observed in the perfusate of either grafts (p > 0.05). By scanning electron microscopy, 
numerous platelet aggregates were observed on the ePTFE grafts, whereas just a few 
adhered platelets and no aggregates were observed in the elastomer grafts.
Conclusions
The elastomer in its current formulation has a low thrombogenicity, comparable to 
ePTFE, making it an ideal substance for endovascular aneurysm sac filling. Further 
research should clarify the feasibility of CAR in vivo.
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INTRODUCTION
Endovascular aneurysm repair (EVAR) of abdominal aortic and other arterial aneurysms 
has become a well-established treatment modality [1, 2]. However, there are still 
several drawbacks to EVAR. Endoleaks, endotension, stent migration and stent failure 
are complications that might lead to re-interventions, prolonged follow-up or even 
rupture after treatment [3, 4]. Furthermore, EVAR has anatomical restrictions. In the 
literature, up to 27% of aneu rysms are considered to be unsuitable for EVAR because of 
insufficient neck length, large neck diameter or severe angulation [5].
To overcome these anatomical disadvantages, Customized Aortic Repair (CAR, 
a concept formerly known as Aortic Customize) was developed as a new approach for 
aneurysm repair (Fig. 1) [6-8]. 
With this concept, the lumen of the aneurysm is excluded by one or more 
endovascular balloon(s), and a non-polymerized liquid elastomeric solution 
(polydimethylsiloxane, PDMS) is used to fill the aneurysm sac around the balloon 
catheter. After the in situ polymerization and balloon deflation, an endoluminal mould 
with a patent lumen excludes the aneurysm sac.
One of the key attributes of this newly engineered elastomer is its low viscosity, 
enabling injection into the aneurysm sac through small profile (7Fr) endovascular 
catheters, resulting in a fully percutaneous, rapid and easily accessible technique. 
Filling the cavity of the aneurysm sac with an injectable biocompatible elastomer 
reduces wall stress and thereby will probably reduce the chance of rupture risk, as 
aneurysm rupture occurs when the local wall stress exceeds the local wall strength 
[6, 9, 10]. Extensive in vitro and preliminary in vivo porcine experiments have shown 
the feasibility and potential of CAR [6, 7, 11]. The elastomer has the physical properties 
necessary for endovascular injection and successful aneurysm exclusion.
The direct contact with blood requires a low thrombogenicity of the 
elastomer to prevent occlusive thrombosis or embolization. Regular PDMS has 
proven its low thrombogenic properties in the past when compared to expanded 
polytetrafluoroethylene (ePTFE) [12]. The elastomer used in CAR is very similar to 
regular PDMS. However, there are no data available on the thrombogenicity of this 
particular elastomer. In advance of any in vivo animal experiments or human clinical 
procedures, further basic research on the thrombogenicity must be performed.
The aim of this human ex vivo study was to measure the thrombogenicity of the 
elastomer in healthy young volunteers and compare it to the thrombogenicity of ePTFE 





In a validated and earlier described ex vivo model, non-anticoagulated blood was drawn 
from the antecubital veins of 10 healthy donors with a 19-gauge needle (Fig. 2) [13]. 
Figure 1. Customized Aneurysm Repair, the treatment concept: A. A schematic drawing of 
an abdominal aortic aneurysm. B. A fill catheter is inserted through a femoral artery. C. An 
endovacular balloon excludes the aneurysm from the circulation. D. The two components of 
the elastomer are pumped in the excluded aneurysm. Excess blood is pushed out alongside the 
balloon. E. After the aneurysm is filled, the elastomer takes 5 min to cure. F. When the elastomer 
has cured, the endovascular balloon is deflated, leaving the aneurysm excluded with a new 
lumen. Reproduced with permission from Bosnian et al. EJVES 2010;40:65-70.
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A vascular graft with a length of 60 cm and a diameter of 3 mm was connected to 
the needle. Using a syringe pump, blood was aspirated with a constant flow rate of 20 ml 
min-1, for 6 min. The combination of this diameter and flow rate resulted in a shear rate 
of 74 s-1, which reflects venous flow conditions and favours fibrin-rich clot formation. 
A cuff was wrapped around the upper arm to ensure a constant pressure of 45 mmHg, 
resulting in a continuous blood flow through the graft during the experiment.
All volunteers were healthy male subjects, who had no vascular history and had 
no coagulopathy. The median age of the volunteers was 24.3 (range: 22—26) years. 
They denied taking any medication 2 weeks before the experiment and gave informed 
consent. The experiments were approved by the local medical ethics committee (UMCU, 
Utrecht, the Netherlands). Every volunteer served as his own control. Randomization of 
the grafts for first and second run took place. When the elastomer graft was used for the 
first run, the ePTFE graft was used for the second run. This second run was performed 
within half an hour after the first run and blood was drawn from the contralateral arm.
Grafts
The elastomer tubes were cast using a custom-made mould (Department of Fine 
Mechanics, Leiden University Medical Center, Leiden, the Netherlands). The elastomer 
Figure 2. Ex vivo perfusion model using a cuff at a constant pressure of 45 mmHg to ensure blood 
flow. Blood is aspirated through the graft with a constant flow of 20 mL/ min, resulting in a shear 
rate of 74/s.
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was a two-component room-temperature addition-cure liquid silicone formulation, 
obtained from Viazym BV (ViaZym BV; Delft, the Netherlands) [8]. The two components 
consisted of:
1. A platinum-containing vinyl-terminated PDMS, surface-treated amorphous 
silica and vinyl Q,
2. A methylhydro-dimethyl-siloxane copolymer containing vinyl-terminated 
PDMS, surface-treated amorphous silica and vinyl Q,
The two components of the elastomer were mixed using a static mixer and injected 
in the mould; creating solid elastomer tubes 60 cm long with an inner diameter of 3 
mm. Standard ePTFE Gore-Tex vascular grafts (Gore, Flagstaff, AZ, USA) with an internal 
diameter of 3 mm and a length of 60 cm were used for comparison.
Blood samples and assays
Blood samples (900 μl) were collected at the end of the graft, starting directly after 
connection to the vein and thereafter every minute for a total of 4 min. After 4 min, 
samples were collected every 30 s until the end of the perfusion (total perfusion time 
was 6 min for each arm). The samples were mixed immediately with 100 μl of 0.5 M 
ethylenediamine tetra acetic acid (EDTA) and centrifuged at 3500 rpm for 5 min, and 
aliquots of plasma were stored at -20 °C until assayed.
Fibrinopeptide A (FPA) and P-selectin levels were determined in the blood 
samples. FPA is the product from the transformation of fibrinogen in fibrin, which is 
a process activated by thrombin release. P-selectin is a cell-adhesion molecule on the 
surfaces of activated endothelial cells, that line the inner surface of blood vessels, and 
activated platelets. When endothelial cells are activated by molecules such as thrombin 
or histamine during injury or inflammation, P-selectin moves from an internal cell 
location to the endothelial cell surface. Therefore FPA- and P-selectin-positive platelets 
are an adequate method to measure the advance of the activated coagulation process.
For the FPA measurements, a commercially available enzyme-linked 
immunosorbent assay was used as an indicator of fibrin formation (Zymutest FPA; 
Hyphen Biomed, Andresy, France). P-selectin expression on perfused platelets, as an 
indicator of activation of platelets, was determined in EDTA anti-coagulated whole 
blood before plasma centrifugation. Platelet activation was assayed by flow cytometric 
analysis using a phycoerythrin (PE)-conjugated monoclonal antibody, following the 
instructions for use of the manufacturer (BD Pharmingen, San Diego, CA, USA, Catalog 
No 555524).
Scanning electron microscopy
The deposition of platelets and fibrin onto the grafts was visualized by scanning electron 
microscopy. The distal end of the graft was cut into small pieces (5x5 mm), fixed in 2% 
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glutaral-dehyde, and then dehydrated through increasing concentrations of ethanol 
(80—100%). The samples were dried with the use of hex-amethyldisilazane. Next, the 
graft pieces were sputter-coated with a thin layer of platinum/palladium and analyzed 
with scanning electron microscopy (Philips XL30; Eindhoven, the Netherlands).
Statistical analysis
The results were analyzed with a paired t test, as implemented in the statistics program 
Statistical Package for the Social Sciences (SPSS) 16.0 for Windows (SPSS Inc., Chicago, IL, 
USA). The results were expressed as the mean ± standard error of the mean (SEM). A P 
value < 0.05 was considered significant.
RESULTS
In the current ex vivo model, non-anticoagulated blood was drawn directly from the 
antecubital veins over either Gore-Tex® ePTFE grafts or elastomer grafts (Fig. 2). All 10 
perfusions were performed without any technical or subject-related complications.
FPA concentration was measured in plasma samples taken at different time 
points. For both graft types, a progressive increase in FPA production was observed in 
time. No significant difference (P > 0.05) was observed between elastomer and ePTFE 
grafts (Fig. 3, Table 1).
The activation of platelets during blood drawing was analyzed by measuring 
the percentage of P-selectin-positive platelets. No increase (P > 0.05), and thereby no 
platelet activation, was observed in the perfusate of either graft (Fig. 4, Table 1).
We also analyzed the results by using each volunteer as his own control, as one 
arm was used for an ePTFE graft and the other arm for an elastomer graft. Fig. 5 shows 
the mean differences (delta values) in FPA- and P-selectin levels per patient. These delta 
values were obtained by subtracting the ePTFE measurements from the elastomer 
values.
Using scanning electron microscopy, numerous platelet aggregates were 
observed on the ePTFE grafts whereas only a few adhered platelets and no aggregates 
were observed in the elastomer grafts (Fig. 6).
DISCUSSION
The measurements of FPA concentration and of P-selectin-positive platelets show that 
the elastomer, designed and tailored for CAR, has a low thrombogenicity. We found 
no statistically significant difference in thrombogenicity compared to ePTFE, one of 
the most used materials in synthetic arterial grafts for aneurysm repair and peripheral 
bypasses (Figs. 3 and 4, Table 1).
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The differences in measured FPA levels and P-selectin percentages per patient 
were minimal as shown in Fig. 5. Individuals who had a ‘strong’ thrombogenic response 
to ePTFE also had a ‘strong’ thrombogenic response to the elastomer. In the same 
manner, individuals who had a ‘moderate’ response to ePTFE, had the same response 
to the elastomer.
The electron microscopic analysis showed a decrease in platelet adhesion and 
aggregation on the elastomer samples compared to ePTFE grafts (Fig. 6). Unfortunately, 
it was not possible to quantify these results. The extremely smooth surface of the 
elastomer graft compared to the porosity of the ePTFE graft could have contributed 
to this difference in the adhesion of platelets. As the use of ePTFE grafts in an aortic 
position has a low thrombosis rate, similar low thrombosis rates can be expected with 
the use of the elastomer.
Figure 3. Fibrinopeptide A measurements show a progressive increase in fibrin formation in time 
during ex vivo perfusions. No significant differences were found between the two types of grafts. 
Error bars indicate standard error of the mean. 
Table 1. P-values of differences in FPA and P-selectin levels measured at different time points. 
The results were analyzed with a paired t test.
FPA P-selectin










123Thrombogenicity of a new elastomer compared to ePTFE
9
Figure 4. P-selectin expression as a measure of platelet activation during ex vivo perfusion. No 
significant increase was observed between the two types of grafts. Error bars indicate standard 
error of the mean.
Figure 5. Graph depicting the difference in the levels of FPA and P-selectin levels in each 
patient (Elastomer value –ePTFE value). Error bars show SD. The delta values were obtained by 
subtracting the ePTFE measurement from the elastomer measurement in each patient.
Figure 6. Scanning electron microscopy of grafts from one single donor. The circles show platelet 
adhesion and aggregation on the grafts after 6 minutes of perfusion with non-anticoagulated 
blood. On the left, the ePTFE specimen, on the right, the elastomer specimen. Pictures are 
representative for all healthy volunteers.
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Limitations of the study
To measure the thrombogenicity of the elastomer, a previously validated human ex vivo 
set-up was used [13]. The main advantage of this ex vivo set-up is that the blood of the 
volunteer does not come in contact with surfaces other than the materials investigated. 
Furthermore, in this set-up, every volunteer was his own control. However, we appreciate 
the fact that every ex vivo experiment is a simplification of the complex in vivo situation. 
The small diameter (3 mm) of the grafts we used is not comparable to the diameter of 
the lower abdominal aorta (±19 mm). However, increased thrombogenicity and vessel 
occlusion is especially a problem occurring in small-diameter vessels as shear stress 
increases and therefore platelet activation and deposition increase. When a small, 
3-mm-diameter graft shows only moderate platelet aggregation or fibrin depositions, it 
is likely that a wider lumen (e.g., 10—20 mm) will not show increased thrombogenicity.
Another difference with the in vivo situation was the average age (24.3 years) 
of the test subjects, while the average age of an aneurysm patient is higher (average 
age 60—80 years). The use of this young age group creates an unreal scenario, with 
regard to the thrombogenicity in the targeted patient group. A young age group was 
however chosen to be sure that the subjects were free of coagulopathic diseases and 
were not on medications that possess thrombogenic properties. For that same reason, 
male subjects were chosen, as they certainly do not take oral contraceptives. The 
high thrombogenicity in this group of young, healthy volunteers would be a major 
drawback of the new technique and would directly limit the use of the elastomer in 
vivo. Furthermore, the use of this age group as test subjects is a validated method in 
comparable thrombogenicity studies [13]. It would certainly be interesting for future 
experiments to repeat the experiments in a more senior age group.
A potential shortcoming of the set-up might be the hypothetical activation of 
the coagulation cascade when the first run of sample collection takes place. This might 
influence the measurements during the second run. In this study and in the earlier 
study with the same ex vivo model, no difference was shown in baseline FPA levels in 
both runs, indicating that systemic coagulation activation by the procedure is unlikely 
[13]. In addition, the randomization of the grafts used in the first and second run should 
have corrected for this potential bias.
Customized Aortic Repair
CAR has been developed to overcome the shortcomings of EVAR, as stated above. 
In an in vitro set-up, it has proven to significantly reduce aneurysmal wall stress [6]. 
When endovascular balloons become available in different forms and configurations, 
in theory, any aneurysm with a deviant anatomy will be treatable with endovascular 
techniques using elastomer sac filling.
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Although new EVAR grafts (e.g., the Endurant and the Aorfix) have been 
launched, which prove the ability to treat severe angulations [14, 15], with many of 
the current EVAR techniques, severe angulations may still lead to kinking of the graft 
material and eventually to migration of the graft [16-18]. As no additional supporting 
graft material is used, these problems are not likely to occur with CAR. The fluidity 
of the non-polymerized elastomer inherently causes adjustment to the geometry 
of the aneurysm, not only by filling the large cavity of the aneurysm sac but also by 
diffusing into all irregularities and side holes. The elastomer mould will attach itself as it 
customizes itself to the form of the abdominal aorta aneurysm (AAA) sac.
Angulation and occlusive disease of the iliac arteries are an important exclusion 
criterion for EVAR, and tortuosity may form a serious obstacle for a successful EVAR 
procedure. A minimal diameter of 12—22 Fr is often needed to access the bulky and 
rigid delivery sheath. To fill the sac with the biocompatible elastomer, a catheter of only 
7 Fr is needed. Preliminary in vivo porcine experiments have shown that this concept is 
technically feasible [7].
Besides the treatment of AAAs, CAR may prove a possible treatment modality for 
thoracic-aorta aneurysms, peripheral aneurysms and iliac aneurysms. With the current 
EVAR techniques, iliac aneurysms can sometimes be difficult to treat due to short distal 
sealing areas, leading to coiling and overstenting of the internal iliac artery. With the 
CAR concept, there is no necessity for a long landing area, and this may prevent the 
necessity to overstent the iliac artery, thereby preventing the introduction of buttock 
claudication and ischemia.
Beside the stand-alone treatment concept, the elastomer injection technique 
is more broadly applicable. The elastomer can already be used as an adjuvant with 
current stent grafts when problems of endoleak or migration occur. In these cases, the 
elastomer can be used to fill up the aneurysm sac and secure the endovascular stent 
graft [11, 19].
The CAR concept is not the only aneurysm treatment concept that addresses 
aneurysm cavity filling. Early in vivo human results with the Nellix have been recently 
published and show promising results [20]. The Nellix concept uses ‘bag-filling’ to fixate 
its 20 Fr grafts with endo-bags in the aneurysm cavity. Although it may seem very 
similar, it is a different concept than the concept presented in the current manuscript, 
as it always needs a bulky graft for aneurysm exclusion. Furthermore, the polymer is 
injected in a closed endo-bag instead of ‘free-range’, thereby limiting its ‘customizing’ 
capabilities. Nevertheless, the Nellix graft has very promising results and may prove to 
be an excellent addition to the abdominal aneurysm treatment modalities.
The elastomer
The elastomer used in this study was designed for aneurysm sac filling in CAR [6-8, 11]. 
It consists of PDMS that has a widespread use in multiple in vivo applications. PDMS 
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is a biocompatible elastomer, and grafts coated with PDMS have shown less graft 
stenosis compared with other grafts [12, 21-25]. The current formula is non-toxic and 
the product cross-links isothermally in the presence of blood, without the release of 
toxic by-products. Viscosity of the compound allowed infusion rates of up to 2 ml s-1 
using a standard angiographic pump with an injection pressure up to 1200 pounds 
per square inch. The substance has an average polymerization time of approximately 5 
min. After curing, the material had a yield stress of approximately 400 kiloPascal (kPa), 
failing at more than 20% elongation. The density of the cured elastomer is 1.0167 g 
crrT3. More details about the development of the current elastomer can be found in an 
earlier publication [7].
Clinical relevance
CAR may prove to be an exciting new endovascular treatment modality to exclude 
different types of aneurysms. As mentioned above, the concept of aneurysm sac filling 
is feasible in several in vitro and in vivo set-ups [6, 7, 11, 19]. Before clinical applications 
can take place, the biocompatibility, biostability and the thrombogenicity have to be 
indisputable. The current study showed that the elastomer has, according to FPA- and 
P-selectin measurements (Figs. 3 and 4), a thrombogenicity comparable to ePTFE, the 
preferred material in synthetic (endo-)vascular grafts. The elastomer tubes seem to be 
superior to the ePTFE tubes with regard to adhesion of platelet aggregates (Fig. 6).
CONCLUSIONS
In conclusion, the elastomer in its current formulation has a low thrombogenicity, 
comparable to the thrombogenicity of ePTFE, in an ex vivo human model. This property 
makes it an ideal substance for endovascular aneurysm sac filling. Further research 
should clarify the thrombogenicity of the elastomer in vivo, as well as the feasibility of 
the novel treatment concept ‘Customized Aortic Repair’ in vivo.
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The aim of this thesis was to evaluate prevalence and clinical sequelae of second 
hip fractures in two areas in the Netherlands (part 1). Secondly, a biomechanical and 
biocompatibility evaluation of elastomer femoroplasty (EF), an experimental technique 
to prevent hip fracture surgery, was performed (part 2 and 3). The introduction and Part 
1 of this thesis discuss the incidence and sequelae of first and second, contralateral hip 
fracture and their social and economic impact. The current incidence of hip fractures 
and the prospected increase in the growing elderly population urgently calls for 
preventive measures. Over the past decades several of these preventive measures have 
been introduced. Programs to prevent falling by balance training [1] or marshal-arts fall 
techniques [2] have promising results and prospective randomized trials on fracture 
prevention by treating osteoporosis with bisphosphonates, vitamin D and calcium 
have shown their efficacy [3-6]. However since the introduction of fall and fracture 
prevention programs, the percentage of second hip fractures has not decreased [7, 8]. 
Furthermore the debate on long-term bisphosphonate use is very contemporary, since 
the report of data on long-term bisphosphonate-use related fractures [9, 10].
Although there is no doubt that major surgery in elderly individuals results 
in functional decline [11, 12], it remains unknown whether second, contralateral hip 
fracture surgery is associated with an additional risk of postoperative complications 
and discharge institutionalization. Chapter 3 describes patient and fracture 
characteristics, the early postoperative complication rate, and the need for discharge 
institutionalization in seventy-one consecutive patients with a second hip fracture at 
the St. Elisabeth Hospital in Tilburg, the Netherlands. Significantly more postoperative 
complications were found after the second hip fracture compared to the first hip 
fracture, with close to twice the number of complications per patient after second, 
contralateral hip fracture surgery. In addition, the complications were more severe 
after second hip fracture surgery than documented after first hip fracture surgery. Only 
approximately one third of the patients were able to return to their own home after 
treatment for second hip fracture. The impact of these sequelae on the patients’ life 
makes contralateral hip fracture prevention mandatory. Particularly when a selection of 
frail patients with increased risk of a second, contralateral hip fracture can be made (i.e. 
older age with weakened motor skills, visual impairment, dementia, respiratory disease 
or solitary life after first hip fracture or radiographic osteoporosis at the hip (the Singh 
Index). These patients will potentially benefit the most from new measures to prevent 
contralateral hip fracture surgery.
In Chapter 4 of Part 2, we present the concept and the surgical technique 
of elastomer femoroplasty (EF). Chapters 5 through 8 discuss the biomechanical 
properties of femoroplasty using an elastomer in an in vitro cadaveric experiment. 
In Chapter 5 we first named the technique “augmentation with silicone”, analog to 
cement augmentation. Augmenting the strength of the proximal femur to prevent a 
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hip fracture with a stiff compound like bone cement (PMMA) increases the load-to-
fracture of the proximal femur [13, 14]. However, in case of failure it could well lead to 
complex fractures below the augmented proximal femur. Fracture surgery after cement 
augmentation will probably be tedious and more extensive with subsequent increased 
morbidity and mortality [15, 16]. The main objective of EF is not to increase resistance 
to load of the proximal femur, in order to prevent a fracture, but to prevent dislocation 
of the fracture parts after hip fracture. Thus allowing primary fracture healing (i.e. 
conservative treatment of the fracture without surgery). That is why a more appropriate 
term for our technique is “elastomer femoroplasty” instead of “augmentation with 
silicone”.
In all our biomechanical experiments human cadaveric femurs conserved in 
formaldehyde were used. From each pair of femurs one was randomly selected for 
femoroplasty and the contralateral hip served as a control. In Chapter 5 we tested the 
load to fracture in a simulated-fall-configuration and the load to dislocation in a single-
leg-stance-configuration. Load was recorded with a load cell in the tensile testing 
machine and dislocation after fracture was calculated using the Neck-Shaft-Angle 
(NSA). The conclusion of this first biomechanical experiment was that the injected 
elastomer did stabilize the proximal femur considering the change of NSA after 
loading as outcome, but it did not augment the proximal hip in a way that the load to 
fracture was increased. In fact there was a non-significant decrease in fracture load of 
approximately 10%. This decrease could well be attributed to the size of the entrance 
hole in the lateral cortex, analog to the increased risk of fracture when a femoral 
metastasis causes a cortical bone lesion [17-19]. Although the size of our entrance in 
the lateral cortex was only 10 mm, it remains a considerable gap especially in smaller 
femurs. This is confirmed by Kukla et al. who showed a decrease in load to fracture of 
the proximal femur by 21% after removal of a dynamic hip screw and by 41% after 
removal of a standard gamma-nail implant in a biomechanical cadaveric study [20]. 
The entrance hole in the lateral cortex could also explain the increase in trochanteric 
fractures in our EF cadaver group. In three of the treated femurs the fracture line passed 
the entrance hole in the lateral cortex.
Thus, refinement of the femoroplasty technique with a smaller entrance 
hole at the lateral cortex was explored. In Chapter 6 two different techniques were 
examined. Both techniques used a 3.5 mm entrance hole in the lateral cortex. Followed 
by a kyphoplasty balloon expanding technique and an excentric drill (Technique A) 
or excentric drill alone (Technique B). The balloons and drills were used to create a 
channel in the femoral neck and a larger cavity in the femoral head. When the cavity 
was filled up with the elastomer, a dog bone like distribution of the elastomer was 
realized. After inducing a fracture, the elastomer kept the fracture parts together. Both 
techniques A and B prevented fracture dislocation. Again there was a non-significant 
load to fracture reduction compared to the controls in both groups. However the load 
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to fracture after EF now only decreased 3.5% for the kyphoplasty balloon and 6.3% for 
the drill technique, compared to 10% in the first experiment with the larger hole at the 
lateral cortex. This reduction was considered to be related to the smaller diameter of 
the entrance hole at the lateral cortex of the proximal femur. In vivo this 3.5 mm defect 
in the lateral cortex is likely to heal by bone formation within a short period of time. The 
balloon technique created a significantly greater cavity for the elastomer, however this 
did not result in significant differences in fracture loads or NSA between both groups. 
The next step to assess the effect of EF in the prevention of hip fracture surgery 
was cyclic loading of the proximal femur-elastomer construct. In Chapter 7, fractured 
human cadaveric femurs that were prophylactically treated with EF (in Chapter 6) were 
cyclically loaded, mimicking walking. The outcome variables were load to failure (i.e. full 
displacement) and displacement during cyclic loading. The mean failure load during 
cyclic loading was 2709 N. This well exceeds peak loads during normal gait in a 75 kg 
individual, which are approximately 1500 – 2025 N [21, 22]. After regular hip fracture 
surgery or hemiarthroplasty these peak loads could even be considerably lower since 
post-operative pain constrains the patient from full weight bearing [23]. In fact Koval 
et al concluded that elderly patients who were allowed to bear weight as tolerated 
after surgical treatment of a fracture of the femoral neck or an intertrochanteric 
fracture, appeared to voluntarily limit loading of the injured limb to 51% during the 
first post-operative week [24]. These patients have to be stimulated to walk and are 
prescribed pain relief medication to gradually reach 87% at 12 weeks. Comparable pain 
and consequent limited loading could be expected after fracture of an EF preventively 
stabilized hip. The above data support the assertion that these EF treated hips have a 
low probability of secondary displacement in case a fracture occurs. 
However, in the event that EF fails to stabilize the fracture parts and secondary 
displacement does occur, or fracture healing is impaired in any other way, some form 
of osteosynthesis or hemiarthroplasty should be possible. Chapter 8 reported the 
feasibility of osteosynthesis of cadaveric femurs after EF with either a Dynamic Hip 
Screw (DHS) or Pertrochanteric Femur Nail Antirotation (PFNA). Neither surgical time 
to perform osteosynthesis nor postoperative loads to failure were different between 
fractured human cadaveric femurs with or without EF. In addition, no technical 
difficulties occurred and no extraordinary surgical instruments were necessary during 
osteosynthesis in the EF-group.
In Chapter 9 the biocompatibility of the elastomer is discussed. The main 
ingredient of the elastomer was Polydimethylsiloxane (PDMS). PDMS is used in multiple 
in vivo applications. It has been widely accepted for bone augmentation in plastic 
surgery because of its variability in hardness (depending on the mix of chemical 
components). Its ability to be easily molded and shaped, and its biological inertness 
[25] makes it ideal for the use in facial implants. Vascular grafts coated with PDMS have 
shown less graft stenosis compared to other vascular grafts [26-29]. 
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To ensure easy injection trough small bore catheters or trocars, the elastomer 
we used was engineered out of two components. After mixing, the elastomer cured 
without exothermic heat or the release of byproducts. Although it is likely for the 
elastomer used in EF to have comparable biocompatibility as PDMS, tests will have 
to confirm its biocompatibility before clinical trails can commence. Furthermore, as 
stated in the introduction, the elastomer should have a low thrombogenicity in case of 
venous embolization or expansion of the elastomer in the extra-osseous capsular veins. 
The elastomer used in femoroplasty is similar to an elastomer used in experiments on 
Customized Aortic Repair (CAR) [30-32]. In these experiments aortic aneurysms were 
treated by injecting elastomer into the sac of an aneurysm. Inflated balloons warrant 
the vascular lumen for blood flow after curing of the elastomer. For this particular 
vascular application of the elastomer, low thrombogenicity was paramount. In the 
experiment reported in Chapter 9, a previously validated human ex vivo set-up was 
used to evaluate the thrombogenicity of our elastomer [33]. The main advantage of 
this ex vivo set-up was that the blood of the volunteer did not come in contact with 
surfaces other than the materials investigated. The results showed that the elastomer 
has, according to FPA- and P-selectin measurements, a thrombogenicity comparable 
to ePTFE, the preferred material in synthetic vascular grafts. The elastomer tubes 
appeared superior to the ePTFE tubes with regard to adhesion of platelet aggregates. 
This experiment confirmed the low thrombogenicity of the elastomer we used in CAR 
and in EF.
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CONCLUSION AND FUTURE DIRECTIONS
Demographic changes will result in a tidal wave of fractures in the growing group 
of frail octo- and nonagenarian citizens. These osteoporotic fractures are a major 
burden to the patients’ quality of life. They will also have a major impact on health care 
recourses. Despite all preventive measures, predominantly focusing on osteoporosis 
medication, the total number of second, contralateral hip fractures has not declined 
over the past decades. Complications and institutionalization after surgery for a second 
hip fracture are increased and can be held responsible for a decrease in quality of life for 
these patients and high healthcare costs. Elastomer femoroplasty is a readily available, 
inexpensive and minimal invasive technique. EF can be applied during ipsilateral hip 
fracture surgery and does not need a separate operation or anesthesia. Furthermore, 
due to the nature of any surgical intervention, patient compliance after EF is 100%. 
Finally, in case of failure of EF to prevent displacement of the fractured hip, it is easy to 
stabilize the fracture with routine osteosynthesis. 
After hip fracture approximately 10% of patients acquire a second, contralateral 
hip fracture. Considering the high rate of complications and the high expenditure on 
costs after second hip fractures compared to the low costs of EF, treating all first hip 
fracture patients with a preventive minimal invasive procedure like EF would probably 
be cost effective. However approximately 90% of patients will be treated without ever 
sustaining a future second hip fracture. Thus, finding and selecting patients with the 
highest risk for second hip fracture through a prediction model (i.e. Markov model) will 
optimize the EF treatment of these patients and increase cost effectiveness. 
We made a major step towards CE marking of the elastomer by proving its 
low thrombogenicity, however further biocompatibility tests will have to be done. 
Animal experiments to determine the effect of EF on bone vasculature and possible 
side effects of intra-osseous injection could be an important next challenge. Finally, 
Roentgen Stereophotogrammetric Analysis (RSA) can be used for the biomechanical 
in vivo testing of the primary bone healing after fracture in EF treated bones. RSA can 
measure fracture displacement in three dimensions in up to 0.1mm and 0.1 degree [34-
36]. These tests can be part of a phased introduction of new medical technologies in 
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Part 1. Sequelae of second hip fracture surgery
Chapter 1 introduces the problem of first and second, contralateral hip fractures. The 
expected growth in incidence of hip fractures in the Netherlands and worldwide, as 
a result of demographic changes is presented. An overview of the current preventive 
modalities aimed at both fall, and fracture prevention is given. Although numerous of 
these preventive modalities have been introduced in the last decades, the incidence of 
second, contralateral hip fractures has not declined. The aim of this thesis is twofold: 1. 
to explore the prevalence and sequelae of second, contralateral hip fractures and 2. a 
biomechanical and biocompatibility evaluation of elastomer femoroplasty (EF).
 The study we present in Chapter 2 is a descriptive analysis of second, contralateral 
hip fractures. For this retrospective study, patients were selected from the database of 
the Leiden University Medical Centre. A total of 32 second, contrlateral hip fractures 
were found and analyzed. First and second hip fracture-types were identical in 75% of 
the patients. However only 8 out of 24 hips were treated with the same implant. There 
was a significant difference in Singh index between both hips at the time of the first 
fracture and between the unfractured hip at the time of the first hip fracture compared 
to itself at the time of the second fracture. We conclude from this small cohort that 
there is a significant effect of the radiographic osteoporosis appearance as measured 
with the Singh index on second proximal femur fracture occurrence.
In Chapter 3 we present a retrospective study to determine early postoperative 
complication rate, and need for institutionalization at time of discharge from the 
hospital in patients treated for a second, contralateral hip fracture. During a six-year 
period (2003-2009) seventy-one patients (60 women and 11 men; age range 54 – 94 
years) underwent first hip fracture surgery and subsequent contralateral hip fracture 
surgery at our hospital. Data from both hospitalization periods were compared. The 
early complication rate in patients sustaining a second, contralateral hip fracture was 
almost twice that documented after the first hip fracture. Following second hip fracture 
surgery, most patients resided in an institutional care facility. 
Part 2. Elastomer femoroplasty.
Chapter 4 introduces elastomer femoroplasty (EF) as a new and experimental modality 
to prevent hip fracture surgery. Using a minimal invasive technique this new approach 
does not aim to prevent the hip fracture itself, but it aims to prevent dislocation after the 
fracture. This should enable bone healing with fracture consolidation conservatively, 
without surgery. In high risk patients EF can be performed during ipsilateral hip fracture 
surgery. A detailed description of the technique is presented in this chapter. 
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 In Chapter 5 we describe our first in vivo biomechanical experiment with EF 
using human cadaver femurs. We randomly assigned 10 paired cadaver femurs for 
elastomer femoroplasty and biomechanically tested for fracture load and dislocation 
against their native contralateral control. A load-testing machine was used for fracture 
induction. All femurs were first fractured in a simulated fall configuration followed 
by dislocation in a “single-leg-stance” configuration. Dislocation was assessed using 
the AO-classification and measuring the Neck-Shaft-Angle’s (NSA). All treated femurs 
showed complete reposition according to NSA after dislocation versus only two of the 
controls (P< 0.001). Unfortunately fracture loads were approximately 10% lower in 
the treated group (P= 0.304). We held the 10 mm entrance hole in the lateral cortex 
accountable for this non-significant difference.
In Chapter 6 we address the above-mentioned possible adverse effect of the 
large entrance hole. Two different minimal invasive EF techniques were designed and 
we compared femur strength and the ability to prevent dislocation of both techniques. 
A total of sixteen fixed human cadaveric femur pairs were used. From each pair one 
femur was randomly assigned for EF. In these femurs we drilled a 3.5 mm entrance 
in the lateral cortex. Cavities for the elastomer were created by: group A, balloon and 
group B an excentric drill. All femurs were fractured by simulating a fall on the greater 
trochanter. Neck-Shaft-Angles on plain anterior posterior radiographs were measured 
to determine fracture displacement. The results of this study show that minimal 
invasive EF prevents fracture displacement of the proximal femur. The compromise 
in load-to-fracture was now less striking, 3.5% for the balloon and 6.3% for the drill 
technique, compared to the 10% drop in our previous experiment. We contributed this 
improvement to the smaller diameter of the entrance hole. 
The aim of the study presented in Chapter 7 was to establish the failure 
loads and interfragmentary movement of fractured, elastomer femoroplasty treated 
femurs during cyclic loading. Sixteen cadaveric femurs were treated with elastomer 
femoroplasty and fractured in a simulated fall configuration. Each specimen underwent 
10 cycles with a preload of 50 Newton (N), starting with a peak load of 250 N followed 
by 10 cycles of 500N and continued with 500N increments. The crosshead speed of 
the testing machine was 2 mm/s. The failure load, the number of completed cycles, 
and crosshead extensions were recorded. The mean failure load was 2709 N (SD 1094). 
At 1500 N (two times the bodyweight of a 75 kg individual) the movement of fracture 
parts was 3.16 mm. Preventive EF leads to stabilization of the proximal femur after 
fracture. In a single leg stance configuration, cyclic loading with mean failure loads that 
well exceed the peak loads during normal gait is feasible. 
In Chapter 8 we describe the feasibility of performing osteosynthesis of a 
fractured hip that has been treated with EF in the event that secondary displacement 
does occur.
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Ten pairs of human cadaveric femurs were fractured in a simulated fall 
configuration. From each pair, one femur was randomly selected for EF prior to 
fracture generation and the contralateral femur was used as control. Following hip 
fracture generation, osteosynthesis was performed in all femurs and the operative 
time, technical difficulties during the procedure, and postoperative failure-load were 
recorded. We found that fixation with routine osteosynthesis of displaced cadaveric hip 
fractures is not hindered by the presence of previously injected elastomer.
Chapter 9 describes an experiment to determine the thrombogenicity of the 
elastomer that we used both in EF and in Customized Aortic Repair (CAR). CAR is a new 
and experimental concept for endovascular aortic aneurysm repair in which a non-
polymerized elastomer is injected to fill the aneurysm sac around a balloon catheter. 
An important part of the biocompatibility of the elastomer is the evaluation of its 
thrombogenicity before further clinical experiments of CAR and EF can take place. The 
aim of this human ex vivo study was to measure the thrombogenicity of the elastomer 
and to compare it to expanded polytetrafluoroethylene (ePTFE) the gold standard for 
prosthesis material in vascular surgery. We used a validated ex vivo model, in witch non-
anticoagulated blood was drawn from the antecubital veins of 10 healthy donors with 
a 19-gauge needle. It was drawn through elastomer tubes and through ePTFE Gore-Tex 
vascular grafts, both 60 cm long and with an inner diameter of 3 mm. Fibrinopeptide A 
(FPA) and P-selectin expression was measured in blood samples, collected at the end of 
the grafts. After the experiments, the deposition of platelets and fibrin onto the grafts 
was visualized by scanning electron microscopy. We found no significant difference 
in thrombogenicity between the elastomer and ePTFE grafts. By scanning electron 
microscopy, numerous platelet aggregates were observed on the ePTFE grafts, whereas 
just a few adhered platelets and no aggregates were observed in the elastomer grafts. 
We concluded that the elastomer in its current formulation has a low thrombogenicity, 
comparable to ePTFE, making it an ideal substance for endovascular aneurysm sac 








In Hoofdstuk 1 van dit proefschrift wordt ter inleiding een overzicht gegeven van 
de prevalentie en de gevolgen van eerste en tweede (contralaterale) heupfracturen. 
Daarnaast worden in dit hoofdstuk hedendaagse fractuur preventie strategieën 
besproken en het povere effect daarvan op de incidentie van tweede heupfracturen.
In Nederland worden jaarlijks ruim 19.000 patiënten opgenomen met een 
heupfractuur. De verwachting is dat dit aantal in de toekomst fors zal toenemen als 
gevolg van demografische veranderingen, met een geschatte wereldwijde prevalentie 
van 6.3 miljoen heupfracturen in het jaar 2050. Eén derde (32%) van de patiënten met 
een heupfractuur overlijdt binnen een jaar, het merendeel hiervan overlijdt in de eerste 
3 maanden. Van de patiënten die wel overleven na een heupfractuur keert de helft 
nooit meer terug tot het niveau van functioneren van vóór de fractuur; 25% van deze 
patiënten verblijft een jaar nadat zij een heupfractuur opliepen nog in een instelling 
voor langdurige zorg, een zeer grote immateriële schade. Het verlies van kwaliteit 
van leven voor deze patiënten en de gevolgen voor hun omgeving zijn aanzienlijk. 
Daarnaast is de behandeling van een heupfractuur ook een dure aangelegenheid. 
Jaarlijks wordt aan de ziekenhuisopnamen van heupfractuurpatiënten ongeveer 500 
miljoen euro besteed. De financiële gevolgen van het verlies van onafhankelijkheid zijn 
nog vele malen groter.
De omvang en de ernst van het probleem vragen om een preventieve aanpak. 
Tot op heden is deze preventieve aanpak gericht op (1) het voorkomen van de val en 
(2) het voorkomen van een fractuur na de val. Valpreventie en balanstraining hebben 
weliswaar een positief effect op het voorkomen van osteoporotische fracturen, maar 
zijn alleen van toepassing op een kleine groep vitale patiënten. Fractuurpreventie door 
medicamenteuze osteoporose behandeling is bewezen effectief in onderzoeksetting. 
Landelijke programma’s om alle patiënten met een osteoporotische fractuur te 
behandelen zijn niet of onvoldoende ingevoerd. Er is dus een grote kans op onder-
behandeling van de osteoporose na een heupfractuur. Daar boven op komt nog 
de matige therapietrouw van medicamenteuze osteoporose behandeling. Andere 
alternatieven zoals de hip-protector (onderbroeken met kussens ter hoogte van 
de heup) en zachte vloeren in verpleeghuizen, zijn inmiddels onderzocht en niet 
effectief bevonden. Deze preventieve maatregelen hebben dan ook geen effect op de 
incidentie van heupfracturen gehad. Ook het percentage tweede heupfracturen is al 
decennia stabiel. Tien tot 16 procent van de ruim 19.000 heupfracturen is een tweede, 
contralaterale, heupfractuur. De beperkte gegevens over de gevolgen van deze tweede 
heupfracturen wijzen uit dat patiënten meer postoperatieve morbiditeit hebben, meer 
invaliditeit en een groter verlies van onafhankelijke mobiliteit. 
In tegenstelling tot val- en fractuurpreventie, is elastomer femoroplasty 
(EF) gericht op de preventie van fractuurdislocatie. Na een heupfractuur voorkomt 
de preventief verrichtte EF dat er dislocatie in de fractuurdelen ontstaat. De 
149Nederlandse Samenvatting
12
heupfractuur kan nu conservatief, dus zonder chirurgie, behandeld worden zoals 
bij een succesvolle behandeling van een geïnclaveerde fractuur. De morbiditeit van 
operatie en ziekenhuisopname blijft de patiënt dan bespaard. Omdat de voorgestelde 
behandeling op zichzelf een extra, zij het minimaal invasieve, operatie is, ligt het voor 
de hand om ons eerst te richten op de preventie van die tweede heupfracturen. Tijdens 
de heupfractuurchirurgie aan de ipsilaterale zijde kan dan de contralaterale heup 
preventief behandeld worden met EF.
Het onderzoek in dit proefschrift brengt de prevalentie en de gevolgen van 
tweede heupfracturen in kaart (deel 1). Daarnaast is de preventie van heupfractuur 
chirurgie door middel van elastomeer femoroplasty (EF) getest in biomechanische en 
biocompatibiliteit studies (deel 2 en 3).
Deel 1. Sequelae van tweede heupfractuur chirurgie
Het verschil in fractuurtype tussen de eerste en tweede heupfractuur en ook het 
verschil in de behandeling wordt uiteengezet in Hoofdstuk 2. In het Leids Universitair 
Medisch Centrum (LUMC) werden de medische dossiers van 32 patiënten met een 
tweede heupfractuur geanalyseerd. Bij 75% van deze patiënten was het type van de 
eerste heupfractuur gelijk aan dat van de contralaterale heupfractuur. De keuze van 
het implantaat voor de behandeling van de twee fracturen was slechts in een derde 
van deze identieke heupfracturen gelijk. Het lijkt waarschijnlijk dat de voorkeur 
van de operateur en de ervaring met het implantaat doorslaggevend zijn voor de 
keuze. Verder wordt in dit hoofdstuk de Singh Index (een eenvoudige meting van de 
botbalkjes op de röntgenfoto van de heup) gebruikt om osteoporose vast te stellen. 
We zien een significante verslechtering van de Singh index tussen de eerste en tweede 
heup fractuur, wat pleit voor direct preventieve behandeling na eerste heupfracturen.
In Hoofdstuk 3 wordt de impact van een tweede heupfractuur op de 
postoperatieve morbiditeit en institutionalisering beschreven. In het St. Elisabeth 
Ziekenhuis in Tilburg werden over een periode van 6 jaar, 920 patiënten opgenomen 
met een heupfractuur. Uit deze groep werden 71 patiënten (8%) geopereerd aan een 
contralaterale heupfractuur. Bijna de helft (46%) van deze tweede heupfracturen vond 
plaats binnen 2 jaar na de eerste heupfractuur. Na een tweede heupfractuur zagen 
we het aantal patiënten met postoperatieve complicaties bijna verdubbelen. Het 
merendeel van de patiënten verloor na een tweede heupfractuur zijn onafhankelijke 
mobiliteit en werd ontslagen naar een verpleeghuis.
Deel 2. Elastomer Femoroplasty
Het concept van elastomer femoroplasty (EF) wordt uitgelegd in Hoofdstuk 4. Via een 
minimaal invasieve, percutane techniek wordt een entree gemaakt in het proximale 
femur. Daarna wordt er ruimte gemaakt in de kop en de hals van het heupbot met een 
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excentrisch boor en/of met een ballontechniek. Hierna wordt een vloeibaar elastomeer 
ingespoten. Dit elastomeer hardt dan in enkele minuten uit tot een flexibele stent in het 
proximale femur. Het uitharden vindt bij lichaamstemperatuur plaats, zonder verdere 
temperatuurstijging of vrijkomen van bijproducten.
Preventieve EF is niet bedoeld om de heupfractuur zelf te voorkomen, maar om 
verplaatsing in de fractuurdelen na een fractuur te minimaliseren. Deze niet-verplaatste 
heupfractuur kan dan genezen zonder dat operatieve fixatie van de fractuurdelen 
nodig is. In de praktijk zal een patiënt die geopereerd moet worden voor een eerste 
heupfractuur, direct preventief behandeld kunnen worden aan de contralaterale kant. 
Gezien het minimaal invasieve karakter van EF en de veronderstelde biocompatibiliteit 
van het elastomeer is te verwachten dat EF aan de contralaterale zijde, minimaal 
additioneel operatierisico met zich meebrengt ten opzichte van het aanzienlijke risico 
van de heupfractuurchirurgie aan de ipsilaterale zijde. 
In Hoofdstuk 5 wordt het in vitro biomechanische experiment met EF 
beschreven. Voor dit onderzoek werden 10 gepaarde kadaverbotten gebruikt. Van elk 
paar werd een femur voor EF behandeling gerandomiseerd, het andere femur diende 
als controle. Vervolgens werden de botten gebroken in een gestandaardiseerde val-
opstelling. Daarna werd de “Neck-Shaft-Angle (NSA)”, dat is de hoek tussen de nek 
en de schacht van het femur, gemeten als uitkomstmaat voor dislocatie. Hoe meer 
de hoek afwijkt van de hoek die vóór de fractuur gemeten werd,  hoe groter de mate 
van dislocatie. Tenslotte werden de botten geplaatst in een opstelling die belasting 
simuleert van staan op één been. De kracht die nodig was om de fractuur te disloceren 
werd gemeten. Hierna werd opnieuw gekeken naar de NSA. De resultaten van deze 
NSA metingen tonen een significante reductie in fractuur-dislocatie in de met EF 
behandelde botten, zowel na fractuur generatie als na belasting op één been. In 
de breekproeven zagen we ook dat de behandelde botten ongeveer 10% minder 
belast konden worden ten opzichte van de onbehandelde controles. Deze daling in 
piekbelasting hebben we toegeschreven aan de 10 mm grootte entree in de laterale 
cortex van de heup waardoor de EF is verricht.
De daling in de belastbaarheid ten gevolge van het 10mm entree bij de EF 
behandelde botten was aanleiding voor het in Hoofdstuk 6 beschreven experiment. 
Het doel was om de entree in de laterale cortex zo klein mogelijk te maken waardoor 
de belasting tot aan het ontstaan van een fractuur minder zou dalen ten opzichte van 
de controles. Hiervoor zijn 2 technieken bedacht die beiden door een entree van 3.5 
mm in de laterale cortex uitgevoerd werden. Opnieuw werd gekozen voor gepaarde 
kadaverbotten (N=16), die binnen elk paar gerandomiseerd werden voor behandeling 
met techniek A of B versus een onbehandelde controle. Techniek A was het creëren 
van een holte voor het elastomeer met een ballon en bij techniek B werd deze holte 
met een excentrische boor gemaakt. Na EF werden beide groepen getest in een 
gestandaardiseerde val-opstelling. De belasting tot aan een fractuur en de NSA vóór 
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en na fractuur werden gemeten. Er was geen significant verschil in belasting tot een 
fractuur tussen de met techniek A of B behandelde botten en hun gepaarde controles. 
Er was ook geen significant verschil tussen groep A en B. De belasting tot een fractuur 
was in groep A gedaald met 3.5% en in groep B met 6.3% ten opzichte van de niet 
behandelde controle-botten. Het is aannemelijk dat deze verbetering ten opzichte van 
de in hoofdstuk 5 beschreven 10% het gevolg is van de kleinere entree in de laterale 
cortex. De mate van dislocatie voor en na fractuur gemeten met NSA, was significant 
beter in de EF behandelde botten; er zat geen verschil in groep A of B. Geconcludeerd 
wordt dat preventieve EF de dislocatie na fractuur voorkomt. 
Hoofdstuk 7 beantwoordt de vraag of een patiënt met een EF voorbehandelde 
en daarna gefractureerde heup zou kunnen mobiliseren. EF behandelde kadaverbotten 
werden gebroken en daarna in een opstelling geplaatst die belasting simuleert van 
het staan op één been. Vervolgens werden de heupen met oplopende krachten belast. 
Steeds werden 10 cyclische belastingen gedaan. Begonnen werd met 250 Newton 
(N) waarna de belasting verhoogd werd naar 500 N, 1000 N, 1500 N etc. De test werd 
gestaakt wanneer de met EF behandelde fractuur faalde. Dit falen werd gedefinieerd 
als een afname van meer dan 5 graden in de NSA (gemeten tussen twee cycli) of een 
abrupte reductie van 50% in de toegepaste gemeten belasting. Tijdens de belasting 
werd de beweging in de fractuur gemeten. Aan het einde van het experiment werden 
de heupbotten opgelost in zoutzuur (H2SO4) om zo alleen het elastomeer over te 
houden. Hierna kon, door onderdompeling in water, het volume van ingespoten 
elastomeer gemeten worden. 
De belasting waarbij de met EF behandelde fracturen faalde was gemiddeld 
2709 Newton. Deze belasting is aanzienlijk hoger dan de normale belasting gemeten 
ter hoogte van de heup tijdens het lopen, i.e. gemiddeld 2 keer het lichaamsgewicht 
of te wel 1500 N bij 75kg. De gemiddelde beweging tussen de fractuurdelen was 3.16 
mm. We vonden geen correlatie tussen de belastbaarheid en het volume elastomeer. 
Dit experiment toont aan dat een gebroken kadaverheup die preventief behandeld is 
met EF, belast kan worden met bijna twee keer zoveel kracht als nodig is bij het lopen. 
Toekomstig in vivo onderzoek moet de preventie van dislocatie na belasting van EF 
behandelde heupen bevestigen.  In Hoofdstuk 8 beschrijven we de mogelijkheden van 
osteosynthese als “back-up” in het geval van een gefaalde preventieve EF na fractuur. 
Bijvoorbeeld in het geval van dislocatie direct na de fractuur (primaire dislocatie) of 
dislocatie na belasting (secundaire dislocatie). Het moet dan alsnog mogelijk zijn 
om met  standaard chirurgische technieken en implantaten deze heupfracturen te 
fixeren. Hiervoor zijn 10 gepaarde kadaverbotten gebruikt. Binnen elk paar werd 
gerandomiseerd voor EF behandeling of controle. De heupen werden gebroken in een 
gestandaardiseerde val-opstelling. Hierna werden de fracturen behandeld met twee 
typen implantaten (DHS of PFNA) afhankelijk van het type fractuur. De tijd die nodig 
was om het implantaat in te brengen werd geregistreerd en technische complicaties 
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werden beschreven. Na het inbrengen van het implantaat werden de heupen getest in 
de staande positie in de testbank. We vonden geen verschil in de operatietijden tussen 
EF en controlegroep en er was ook geen verschil in de belastbaarheid na het inbrengen 
van de implantaten. Er was geen speciaal instrumentarium nodig om het elastomeer te 
verwijderen, in tegenstelling tot bijvoorbeeld bij cement femoroplasty te verwachten 
is. Ook waren geen technische complicaties bij het inbrengen van de implantaten. Dit 
onderzoek bevestigt ons vermoeden dat er geen beletsel is voor het inbrengen van 
een implantaat in het geval van dislocatie na preventieve EF behandeling.
In Hoofdstuk 9 wordt de trombogeniciteit van het voor EF gebruikte elastomeer 
beschreven. Het elastomeer dat gebruikt is in EF is identiek aan het elastomeer dat 
gebruikt wordt voor de applicatie “Customized Aortic Repair (CAR)”. De trombogeniciteit 
als onderdeel van de biocompatibiliteit van het elastomeer is van belang voor de 
toepassing van CAR, aangezien het elastomeer bij deze toepassing direct in de bloedbaan 
wordt gebracht. Daarnaast zou trombogeniciteit en zeker hyper-trombogeniciteit van 
het elastomeer een rol kunnen spelen bij EF. In het geval van hyper-trombogeniciteit 
zou onverhoopte lekkage van elastomeer richting het veneuze systeem bijvoorbeeld 
kunnen leiden tot veneuze trombose. In dit onderzoek hebben we gekeken naar de 
expressie van de stollingsfactoren Fibrinopeptide A (FPA) en P-selectin in het bloed 
van gezonde vrijwilligers. We hebben een eerder gevalideerd ex-vivo model gebruikt 
waarbij het bloed werd geaspireerd uit een vene in de elleboogplooi, door een buisje 
gemaakt van elastomeer. De controle was de andere arm van de gezonde vrijwilliger 
en een buisje van ePTFE, dit is de gouden standaard kunststof in bypass chirurgie. Het 
bloed werd met vaste intervallen opgevangen aan het einde van het elastomeer of 
ePTFE buisje. In deze samples werden de FPA en P-selectin gemeten. Uit deze metingen 
blijkt dat het gebruikte elastomeer een lage trombogeniciteit heeft, vergelijkbaar met 





Demografische veranderingen gaan in de komende decennia leiden tot een toename 
van het aantal heupfracturen. Deze fracturen hebben een hoge mortaliteit (tot 30% 
in het eerste jaar), maar hebben vooral een enorm negatieve impact op de kwaliteit 
van leven van de patiënt en zijn omgeving. Ondanks de tot op heden ingestelde 
preventieve maatregelen, met name gefocust op de medicamenteuze behandeling van 
osteoporose, neemt de prevalentie van eerste en tweede heupfracturen niet af. Juist 
bij de behandeling van die tweede heupfracturen zijn de postoperatieve complicaties 
bijna verdubbeld en is er een toegenomen institutionalisering na ontslag uit het 
ziekenhuis. Het ligt dan ook voor de hand om ons eerst te richten op de preventie van 
tweede heupfractuur chirurgie. EF contralateraal ingebracht tijdens de ipsilaterale 
chirurgie geeft dan een direct preventief effect, het is niet duur en er is geen extra 
operatiezitting of extra anesthesie nodig. De toegenomen morbiditeit wordt zeer laag 
ingeschat. In biomechanische en biocompatibiliteits experimenten beschreven in dit 
proefschrift is de effectiviteit van EF als preventieve modaliteit in vitro aangetoond.
Toekomstig onderzoek naar de effectiviteit en veiligheid van EF in vivo lijkt een 
logische stap. Bij elke preventieve behandeling moeten de negatieve effecten van die 
behandeling voor degene die de behandeling nooit nodig hebben, in evenwicht zijn 
met de positieve effecten bij degene die de behandeling wel nodig blijken te hebben 
(10-16% tweede heupfracturen). Het preventief behandelen van alle contralaterale 
heupen met EF tijdens de eerste fractuur zou dus een aanzienlijke overbehandeling 
kunnen betekenen (84% - 90%). Echter door de minimale extra belasting en lage 
kosten van EF enerzijds, en een groot verlies aan kwaliteit van leven en hoge kosten bij 
een tweede heupfractuur anderzijds, zal contralaterale EF bij alle eerste heupfracturen 
zeker effectief blijken. Door nauwkeurige selectie van patiënten met het hoogste risico 
op een tweede heupfractuur, zal de effectiviteit van de preventieve behandeling met 
EF nog verder stijgen.
Dierexperimenteel onderzoek naar het effect van EF op de vascularisatie van het 
omliggende bot en mogelijke systemische en trombo-embolische bijwerkingen van 
intra-ossale toediening van het elastomeer kunnen belangrijke nieuwe stappen zijn. 
Daarnaast kunnen we door gebruik te maken van Roentgen Stereophotogrammetric 
Analysis (RSA) een indruk krijgen van de genezing van een fractuur in een preventief 
met EF behandelde heup. Met RSA kunnen in 3 dimensies verplaatsingen van 
de fractuurdelen tot 0.1mm en 0.1 graden gemeten worden. Bovengenoemde 
onderzoekingen zullen onderdeel zijn van een gefaseerde introductie van deze 
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